JPWO2021030657A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021030657A5 JPWO2021030657A5 JP2022507875A JP2022507875A JPWO2021030657A5 JP WO2021030657 A5 JPWO2021030657 A5 JP WO2021030657A5 JP 2022507875 A JP2022507875 A JP 2022507875A JP 2022507875 A JP2022507875 A JP 2022507875A JP WO2021030657 A5 JPWO2021030657 A5 JP WO2021030657A5
- Authority
- JP
- Japan
- Prior art keywords
- cys
- scfv
- seq
- exposed
- disulfide bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
この実施例は、本明細書に提供される多重特異性結合分子を介してLTBRを活性化するアプローチ、例えば、細胞外マトリックスに関連するLTBR及び腫瘍関連抗原の両方への結合が、それ以上試験された細胞外マトリックスの3つの異なる腫瘍関連抗原すべてに対して機能し、したがって、細胞外マトリックスに存在する腫瘍関連抗原には一般に適用可能であることを実証した。本実施例はまた、spFvを組み込んだ分子が機能的であることを実証した。
以下の態様を包含し得る。
[1] 重鎖可変領域(VH)、リンカー(L)及び軽鎖可変領域(VL)を含む単離された単鎖可変断片(scFv)であって、
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合、及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、scFv。
[2] VH、L及びVLを含む単離されたscFvであって、
a)前記VHが、構造的に保存された表面露出VHフレームワーク残基位置にVH Cysを含み、前記Lが、第1のL Cysを含むか、
b)前記VLが、構造的に保存された表面露出VLフレームワーク残基位置にVL Cysを含み、前記Lが、第2のL Cysを含むか、又は
c)前記VHが、構造的に保存された表面露出VHフレームワーク残基位置に前記VH Cysを含み、前記VLが、構造的に保存された表面露出VLフレームワーク残基位置に前記VL Cysを含み、前記Lが、前記第1のL Cys及び前記第2のL Cysを含み、前記VH Cys及び前記第1のL Cysが、ジスルフィド結合を形成することができ、前記VL Cys及び前記第2のL Cysが、ジスルフィド結合を形成することができる、単離されたscFv。
[3] 前記VH Cysと前記VL Cysとの間の距離が、約7Å~約9Åである、上記[1]又は[2]に記載のscFv。
[4] 前記VH Cysが、H3、H5、H40、H43、H46又はH105にあり、残基番号付けは、Chothiaに従う、上記[1]~[3]のいずれか一項に記載のscFv。
[5] 前記VL Cysが、L3、L5、L39、L42、L45、L100又はL102にあり、残基番号付けは、Chothiaに従う、上記[1]~[4]のいずれか一項に記載のscFv。
[6] a)前記VH CysがH105にあり、前記VL CysがL42にあるか、
b)前記VH CysがH43にあり、前記VL CysがL100にあるか、
c)前記VH CysがH3にあり、前記VL CysがL3にあるか、
d)前記VH CysがH3にあり、前記VL CysがL5にあるか、
e)前記VH CysがH3にあり、前記VL CysがL39にあるか、
f)前記VH CysがH3にあり、前記VL CysがL42にあるか、
g)前記VH CysがH3にあり、前記VL CysがL45にあるか、
h)前記VH CysがH3にあり、前記VL CysがL100にあるか、
i)前記VH CysがH3にあり、前記VL CysがL102にあるか、
j)前記VH CysがH5にあり、前記VL CysがL3にあるか、
k)前記VH CysがH5にあり、前記VL CysがL5にあるか、
l)前記VH CysがH5にあり、前記VL CysがL39にあるか、
m)前記VH CysがH5にあり、前記VL CysがL42にあるか、
n)前記VH CysがH5にあり、前記VL CysがL45にあるか、
o)前記VH CysがH5にあり、前記VL CysがL100にあるか、
p)前記VH CysがH5にあり、前記VL CysがL102にあるか、
q)前記VH CysがH40にあり、前記VL CysがL3にあるか、
r)前記VH CysがH40にあり、前記VL CysがL5にあるか、
s)前記VH CysがH40にあり、前記VL CysがL39にあるか、
t)前記VH CysがH40にあり、前記VL CysがL42にあるか、
u)前記VH CysがH40にあり、前記VL CysがL45にあるか、
v)前記VH CysがH40にあり、前記VL CysがL100にあるか、
w)前記VH CysがH40にあり、前記VL CysがL102にあるか、
x)前記VH CysがH43にあり、前記VL CysがL3にあるか、
y)前記VH CysがH43にあり、前記VL CysがL5にあるか、
z)前記VH CysがH43にあり、前記VL CysがL39にあるか、
aa)前記VH CysがH43にあり、前記VL CysがL42にあるか、
bb)前記VH CysがH43にあり、前記VL CysがL45にあるか、
cc)前記VH CysがH43にあり、前記VL CysがL102にあるか、
dd)前記VH CysがH46にあり、前記VL CysがL3にあるか、
ee)前記VH CysがH46にあり、前記VL CysがL5にあるか、
ff)前記VH CysがH46にあり、前記VL CysがL39にあるか、
gg)前記VH CysがH46にあり、前記VL CysがL42にあるか、
hh)前記VH CysがH46にあり、前記VL CysがL45にあるか、
ii)前記VH CysがH46にあり、前記VL CysがL100にあるか、
jj)前記VH CysがH46にあり、前記VL CysがL102にあるか、
kk)前記VH CysがH105にあり、前記VL CysがL3にあるか、
ll)前記VH CysがH105にあり、前記VL CysがL5にあるか、
mm)前記VH CysがH105にあり、前記VL CysがL39にあるか、
nn)前記VH CysがH105にあり、前記VL CysがL45にあるか、
oo)前記VH CysがH105にあり、前記VL CysがL100にあるか、又は
pp)前記VH CysがH105にあり、前記VL CysがL102にあり、残基番号付けがChothiaに従う、上記[1]~[5]のいずれか一項に記載のscFv。
[7] 前記Lが、免疫グロブリン(Ig)ヒンジ領域に由来する連続アミノ酸配列を含む、上記[1]~[6]のいずれか一項に記載のscFv。
[8] 前記Igヒンジ領域が、ヒト又は非ヒトIgヒンジ領域に由来する、上記[7]に記載のscFv。
[9] 前記Igヒンジ領域が、前記ヒトIgヒンジ領域に由来する、上記[8]に記載のscFv。
[10] 前記ヒトIgヒンジ領域が、IgG1、IgG2、IgG3又はIgG4アイソタイプである、上記[9]に記載のscFv。
[11] 前記Lが、アミノ酸配列C(X)
y
C(配列番号23)を含み、式中、Xは、グリシン(Gly)、セリン(Ser)、プロリン(Pro)、アラニン(Ala)、アルギニン(Arg)、アスパラギン(Asn)、アスパラギン酸(Asp)、グルタミン酸(Glu)、グルタミン(Gln)、ヒスチジン(His)、イソロイシン(Ile)、ロイシン(Leu)、リジン(Lys)、フェニルアラニン(Phe)、スレオニン(Thr)、トリプトファン(Trp)又はチロシン(Tyr)であり、yは、1~3の整数である、上記[1]~[10]のいずれか一項に記載のscFv。
[12] 前記Lが、アミノ酸配列C(X)
y
C(配列番号24)を含み、式中、Xは、Gly、Ser又はProであり、yは、1~3の整数である、上記[11]に記載のscFv。
[13] 前記Lが、前記アミノ酸配列CPC、CGC、CSC、CPPC(配列番号1)、CGPC(配列番号28)、CPGC(配列番号29)、CGGC(配列番号30)、CSPG(配列番号31)、CPSC(配列番号32)、CSSC(配列番号33)、CGSC(配列番号34)、CSGC(配列番号35)、CPPPC(配列番号36)、CGPPC(配列番号37)、CPGPC(配列番号38)、CPPGC(配列番号39)、CGGPC(配列番号40)、CPGGC(配列番号41)、CGGGC(配列番号42)、CSPPC(配列番号43)、CPSPC(配列番号44)、CPPSC(配列番号45)、CSSPC(配列番号46)、CPSSC(配列番号47)、CSSSC(配列番号48)、CGSPC(配列番号49)、CPGSC(配列番号50)、CSGPC(配列番号51)又はCPSGC(配列番号52)を含む、上記[1]~[12]のいずれか一項に記載のscFv。
[14] 前記Lが、約14~約19アミノ酸、例えば、約14、約15、約16、約17、約18、又は約19アミノ酸を含む、上記[1]~[13]のいずれか一項に記載のscFv。
[15] 前記Lが、アミノ酸配列(X)
m
C(X)
y
C(X)
n
(配列番号25)を含み、式中、Xは、Gly、Ser、Pro、Ala、Arg、Asn、Asp、Glu、Gln、His、Ile、leu、Lys、Phe、Thr、Trp又はTyrであり、mは、6~9の整数であり、yは、1~3の整数であり、nは、4~6の整数である、上記[1]~[14]のいずれか一項に記載のscFv。
[16] 前記Lが、アミノ酸配列(X)
m
C(X)
y
C(X)
n
(配列番号26)を含み、式中、Xは、Gly、Ser、Pro、Ala、Arg、Asn、Asp、Glu、Gln、His、Ile、Leu、Lys、Thr又はTyrであり、mは、6~9の整数であり、yは、1~3の整数であり、nは、4~6の整数である、上記[15]に記載のscFv。
[17] 前記Lが、アミノ酸配列(X)
m
C(X)
y
C(X)
n
(配列番号27)を含み、式中、Xは、Gly又はProであり、mは、6~9の整数であり、yは、1~3の整数であり、nは、4~6の整数である、上記[16]に記載のscFv。
[18] 前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含む、上記[1]~[17]のいずれか一項に記載のscFv。
[19] 前記scFvが、VL-L-VH配向にある、上記[1]~[18]のいずれか一項に記載のscFv。
[20] 前記scFvが、VH-L-VL配向にある、上記[1]~[18]のいずれか一項に記載のscFv。
[21] VH、L、及びVLを含むscFvであって、
a)前記VHが、H105にCysを含み、
b)前記VLが、L42にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にある、scFv。
[22] VH、L、及びVLを含むscFvであって、
a)前記VHが、H105にCysを含み、
b)前記VLが、L45にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にある、scFv。
[23] VH、L、及びVLを含むscFvであって、
a)前記VHが、H105にCysを含み、
b)前記VLが、L39にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にある、scFv。
[24] VH、L、及びVLを含むscFvであって、
a)前記VHが、H5にCysを含み、
b)前記VLが、L42にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にある、scFv。
[25] VH、L、及びVLを含むscFvであって、
a)前記VHが、H5にCysを含み、
b)前記VLが、L45にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にある、scFv。
[26] VH、L、及びVLを含むscFvであって、
a)前記VHが、H5にCysを含み、
b)前記VLが、L39にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にある、scFv。
[27] VH、L、及びVLを含むscFvであって、
a)前記VHが、H3にCysを含み、
b)前記VLが、L42にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にある、scFv。
[28] VH、L、及びVLを含むscFvであって、
a)前記VHが、H3にCysを含み、
b)前記VLが、L45にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にある、scFv。
[29] VH、L、及びVLを含むscFvであって、
a)前記VHが、H3にCysを含み、
b)前記VLが、L39にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にある、scFv。
[30] VH、L、及びVLを含むscFvであって、
a)前記VHが、H43にCysを含み、
b)前記VLが、L100にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[31] VH、L、及びVLを含むscFvであって、
a)前記VHが、H43にCysを含み、
b)前記VLが、L102にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[32] VH、L、及びVLを含むscFvであって、
a)前記VHが、H43にCysを含み、
b)前記VLが、L5にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[33] VH、L、及びVLを含むscFvであって、
a)前記VHが、H43にCysを含み、
b)前記VLが、L3にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[34] VH、L、及びVLを含むscFvであって、
a)前記VHが、H40にCysを含み、
b)前記VLが、L100にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[35] VH、L、及びVLを含むscFvであって、
a)前記VHが、H40にCysを含み、
b)前記VLが、L102にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[36] VH、L、及びVLを含むscFvであって、
a)前記VHが、H40にCysを含み、
b)前記VLが、L5にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[37] VH、L、及びVLを含むscFvであって、
a)前記VHが、H40にCysを含み、
b)前記VLが、L3にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[38] VH、L、及びVLを含むscFvであって、
a)前記VHが、H46にCysを含み、
b)前記VLが、L100にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[39] VH、L、及びVLを含むscFvであって、
a)前記VHが、H46にCysを含み、
b)前記VLが、L102にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[40] VH、L、及びVLを含むscFvであって、
a)前記VHが、H46にCysを含み、
b)前記VLが、L5にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[41] VH、L、及びVLを含むscFvであって、
a)前記VHが、H46にCysを含み、
b)前記VLが、L3にCysを含み、
c)前記Lが、配列番号2、3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、scFv。
[42] 前記Lが、配列番号3のアミノ酸配列を含む、上記[21]~[41]のいずれか一項に記載のscFv。
[43] 前記Lが、配列番号6のアミノ酸配列を含む、上記[21]~[41]のいずれか一項に記載のscFv。
[44] 前記Lが、配列番号7のアミノ酸配列を含む、上記[21]~[41]のいずれか一項に記載のscFv。
[45] 前記scFvが、第2の分子に共役される、上記[1]~[44]のいずれか一項に記載のscFv。
[46] 前記第2の分子が、半減期延長部分である、上記[45]に記載のscFv。
[47] 前記半減期延長部分が、免疫グロブリン(Ig)、前記Igの断片、Ig定常領域、前記Ig定常領域の断片、Fc領域、トランスフェリン、アルブミン、アルブミン結合ドメイン又はポリエチレングリコールである、上記[46]に記載のscFv。
[48] 前記第2の分子が、細胞傷害性薬剤又は検出可能な標識である、上記[45]に記載のscFv。
[49] 前記第2の分子が、抗体又はその断片である、上記[48]に記載のscFv。
[50] 前記scFv及び前記抗体又は前記その断片が、異なる抗原に結合している、上記[49]に記載のscFv。
[51] 前記第2の分子が、キメラ抗原受容体(CAR)である、上記[45]に記載のscFv。
[52] 上記[1]~[51]のいずれか一項に記載のscFvと、薬学的に許容される担体と、を含む、医薬組成物。
[53] 上記[1]~[44]のいずれか一項に記載のscFvをコードする、ポリヌクレオチド。
[54] 上記[53]に記載のポリヌクレオチドを含む、ベクター。
[55] 上記[54]に記載のベクターを含む、宿主細胞。
[56] 上記[1]~[44]のいずれか一項に記載のscFvを産生する方法であって、前記scFvが産生される条件で上記[55]に記載の宿主細胞を培養することと、前記scFvを精製することと、を含む、方法。
[57] 前記宿主細胞が、原核細胞である、上記[56]に記載の方法。
[58] 前記宿主細胞が、真核細胞である、上記[56]に記載の方法。
[59] 上記[1]~[44]のいずれか一項に記載のscFvに結合する、抗イディオタイプ抗体。
[60] 上記[1]~[44]のいずれか一項に記載のscFvを含む、キット。
[61] 上記[1]~[44]のいずれか一項に記載のscFvを含む、多重特異性分子。
[62] 前記多重特異性分子が、抗体又は抗体断片を含む、上記[61]に記載の多重特異性分子。
[63] 前記多重特異性タンパク質が、Ig定常領域又は前記Ig定常領域の断片を含む、上記[61]に記載の多重特異性分子。
[64] 前記Ig定常領域の前記断片が、Fc領域を含む、上記[63]に記載の多重特異性タンパク質。
[65] 前記Ig定常領域の前記断片が、CH2ドメインを含む、上記[63]に記載の多重特異性分子。
[66] 前記Ig定常領域の前記断片が、CH3ドメインを含む、上記[63]に記載の多重特異性分子。
[67] 前記Ig定常領域の前記断片が、前記CH2ドメインと、前記CH3ドメインと、を含む、上記[63]に記載の多重特異性分子。
[68] 前記Ig定常領域の前記断片が、ヒンジの少なくとも一部分、前記CH2ドメイン及び前記CH3ドメインを含む、上記[63]に記載の多重特異性分子。
[69] 前記Ig定常領域の前記断片が、前記ヒンジと、前記CH2ドメインと、前記CH3ドメインと、を含む、上記[63]に記載の多重特異性分子。
[70] 前記scFvが、前記Ig定常領域のN末端又は前記Ig定常領域の前記断片のN末端に共役される、上記[63]~[69]のいずれか一項に記載の多重特異性分子。
[71] 前記scFvが、前記Ig定常領域のC末端又は前記Ig定常領域の前記断片のN末端に共役される、上記[63]~[69]のいずれか一項に記載の多重特異性分子。
[72] 前記Ig定常領域又は前記Ig定常領域の前記断片が、IgG1、IgG2、及びIgG3又はIgG4アイソタイプである、上記[63]~[71]のいずれか一項に記載の多重特異性分子。
[73] 前記Ig定常領域又は前記Ig定常領域の前記断片が、前記多重特異性分子のFcγRへの結合を低減する少なくとも1つの変異を含む、上記[63]~[72]のいずれか一項に記載の多重特異性分子。
[74] 前記多重特異性分子のFcγRへの結合を低減する前記少なくとも1つの変異が、F234A/L235A、L234A/L235A、L234A/L235A/D265S、V234A/G237A/P238S/H268A/V309L/A330S/P331S、F234A/L235A、S228P/F234A/L235A、N297A、V234A/G237A、K214T/E233P/L234V/L235A/G236-欠失/A327G/P331A/D365E/L358M、H268Q/V309L/A330S/P331S、S267E/L328F、L234F/L235E/D265A、L234A/L235A/G237A/P238S/H268A/A330S/P331S、S228P/F234A/L235A/G237A/P238S及びS228P/F234A/L235A/G236-欠失/G237A/P238Sからなる群から選択され、残基番号付けが、EUインデックスに従う、上記[73]に記載の多重特異性分子。
[75] 前記Ig定常領域又は前記Ig定常領域の前記断片が、前記多重特異性分子のFcγRへの結合を増強する少なくとも1つの変異を含む、上記[63]~[72]のいずれか一項に記載の多重特異性分子。
[76] 前記多重特異性分子のFcγRへの結合を増強する前記少なくとも1つの変異が、S239D/I332E、S298A/E333A/K334A、F243L/R292P/Y300L、F243L/R292P/Y300L/P396L、F243L/R292P/Y300L/V305I/P396L及びG236A/S239D/I332Eからなる群から選択され、残基番号付けが、EUインデックスに従う、上記[75]に記載の多重特異性分子。
[77] FcγRが、FcγRI、FcγRIIA、FcγRIIB若しくはFcγRIII、又はそれらの任意の組み合わせである、上記[73]~[76]のいずれか一項に記載の多重特異性分子。
[78] 前記Ig定常領域又は前記Ig定常領域の断片が、前記多重特異性分子の半減期を調節する少なくとも1つの変異を含む、上記[63]~[72]のいずれか一項に記載の多重特異性分子。
[79] 前記多重特異性分子の前記半減期を調節する前記少なくとも1つの変異が、H435A、P257I/N434H、D376V/N434H、M252Y/S254T/T256E/H433K/N434F、T308P/N434A及びH435Rからなる群から選択され、残基番号付けが、EUインデックスに従う、上記[78]に記載の多重特異性分子。
[80] 前記Ig定常領域又は前記Ig定常領域の断片が、前記CH3ドメインに少なくとも1つの変異を含む、上記[63]~[72]のいずれか一項に記載の多重特異性分子。
[81] 前記CH3ドメインにおける前記少なくとも1つの変異が、T350V、L351Y、F405A、Y407V、T366Y、T366W、F405W、T394W、T394S、Y407T、Y407A、T366S/L368A/Y407V、L351Y/F405A/Y407V、T366I/K392M/T394W、F405A/Y407V、T366L/K392M/T394W、L351Y/Y407A、T366A/K409F、L351Y/Y407A、T366V/K409F、T366A/K409F、T350V/L351Y/F405A/Y407V及びT350V/T366L/K392L/T394Wからなる群から選択され、残基番号付けが、EUインデックスに従う、上記[80]に記載の多重特異性分子。
[82] 前記多重特異性分子が、二重特異性である、上記[61]~[81]のいずれか一項に記載の多重特異性分子。
[83] 前記多重特異性分子が、三重特異性である、上記[61]~[81]のいずれか一項に記載の多重特異性分子。
[84] 前記多重特異性分子が、四重特異性である、上記[61]~[81]のいずれか一項に記載の多重特異性分子。
[85] 上記[61]~[84]のいずれか一項に記載の多重特異性分子及び薬学的に許容される担体を含む、医薬組成物。
[86] 上記[1]~[44]のいずれか一項に記載のscFvを含む、異種分子。
[87] 前記scFvが、第2のタンパク質、ポリヌクレオチド、治療薬、細胞傷害性薬剤又は検出可能な標識に共役される、上記[86]に記載の異種分子。
[88] 前記第2のタンパク質が、抗体又はその断片である、上記[87]に記載の異種分子。
[89] 前記第2のタンパク質が、代替スカフォールドである、上記[87]に記載の異種分子。
[90] 前記第2のタンパク質が、キメラ抗原受容体(CAR)又はその断片である、上記[87]に記載の異種分子。
[91] 前記異種分子が、単一特異性である、上記[86]~[90]のいずれか一項に記載の異種分子。
[92] 前記異種分子が、多重特異性である、上記[86]~[90]のいずれか一項に記載の異種分子。
[93] 前記異種分子が、二重特異性である、上記[92]に記載の異種分子。
[94] 前記異種分子が、三重特異性である、上記[92]に記載の異種分子。
[95] 前記異種分子が、四重特異性である、上記[92]に記載の異種分子。
[96] 上記[86]~[95]のいずれか一項に記載の異種分子と、薬学的に許容される担体と、を含む、医薬組成物。
[97] 安定化scFvを調製するためのプロセスであって、
抗原結合ドメインを形成する重鎖可変領域(VH)及び軽鎖可変領域(VL)を提供することと、
第1のL Cysを含むか、又はそれを含むように操作されたリンカー(L)を提供することと、
構造的に保存された表面露出VHフレームワーク残基位置でVH Cysを含むように前記VHを操作することと、
前記VH Cysと前記第1のL Cysとの間にジスルフィド結合を形成して、前記安定化scFvを調製することと、を含む、プロセス。
[98] 安定化scFvを調製するためのプロセスであって、
抗原結合ドメインを形成するVH及びVLを提供することと、
第2のL Cysを含むか、又はそれを含むように操作されたLを提供することと、
構造的に保存された表面露出VLフレームワーク残基位置にVL Cysを含むように前記VLを操作することと、
前記VL Cysと前記第2のL Cysとの間にジスルフィド結合を形成して、前記安定化scFvを調製することと、を含む、プロセス。
[99] 安定化scFvを調製するためのプロセスであって、
抗原結合ドメインを形成するVH及びVLを提供することと、
第1のL Cys及び第2のL Cysを含むか、又はそれらを含むように操作されたLを提供することと、
構造的に保存された表面露出VHフレームワーク残基位置にVH Cysを含むように前記VHを操作することと、
構造的に保存された表面露出VLフレームワーク残基位置にVL Cysを含むように前記VLを操作することと、
前記VH Cysと前記第1のL Cysとの間にジスルフィド結合を形成し、前記VL Cysと前記第2のL Cysとの間にジスルフィド結合を形成して、前記安定化scFvを調製することと、を含む、プロセス。
[100] 前記安定化scFvが、上記[1]~[44]のいずれか一項に記載のscFvである、上記[97]~[99]のいずれか一項に記載のプロセス。
[101] 前記安定化scFvが、前記ジスルフィド結合を欠いている対照scFvと比較した場合、同等の親和性で抗原に結合する、上記[97]~[100]のいずれか一項に記載のプロセス。
[102] 安定化scFvを調製するためのプロセスであって、
a)VH、L及びVLをコードするポリヌクレオチドを提供することであって、
i.前記VHが、H105にCysを含み、前記VLが、L42にCysを含むか、
ii.前記VHが、H43にCysを含み、前記VLが、L100にCysを含むか、
iii.前記VHが、H3にCysを含み、前記VLが、L3にCysを含むか、
iv.前記VHが、H3にCysを含み、前記VLが、L5にCysを含むか、
v.前記VHが、H3にCysを含み、前記VLが、L39にCysを含むか、
vi.前記VHが、H3にCysを含み、前記VLが、L42にCysを含むか、
vii.前記VHが、H3にCysを含み、前記VLが、L45にCysを含むか、
viii.前記VHが、H3にCysを含み、前記VLが、L100にCysを含むか、
ix.前記VHが、H3にCysを含み、前記VLが、L102にCysを含むか、
x.前記VHが、H5にCysを含み、前記VLが、L3にCysを含むか、
xi.前記VHが、H5にCysを含み、前記VLが、L5にCysを含むか、
xii.前記VHが、H5にCysを含み、前記VLが、L39にCysを含むか、
xiii.前記VHが、H5にCysを含み、前記VLが、L42にCysを含むか、
xiv.前記VHが、H5にCysを含み、前記VLが、L45にCysを含むか、
xv.前記VHが、H5にCysを含み、前記VLが、L100にCysを含むか、
xvi.前記VHが、H5にCysを含み、前記VLが、L102にCysを含むか、
xvii.前記VHが、H40にCysを含み、前記VLが、L3にCysを含むか、
xviii.前記VHが、H40にCysを含み、前記VLが、L5にCysを含むか、
xix.前記VHが、H40にCysを含み、前記VLが、L39にCysを含むか、
xx.前記VHが、H40にCysを含み、前記VLが、L42にCysを含むか、
xxi.前記VHが、H40にiCysを含み、前記VLが、L45にCysを含むか、
xxii.前記VHが、H40にCysを含み、前記VLが、L100にCysを含むか、
xxiii.前記VHが、H40にCysを含み、前記VLが、L102にCysを含むか、
xxiv.前記VHが、H43にCysを含み、前記VLが、L3にCysを含むか、
xxv.前記VHが、H43にCysを含み、前記VLが、L5にCysを含むか、
xxvi.前記VHが、H43にCysを含み、前記VLが、L39にCysを含むか、
xxvii.前記VHが、H43にCysを含み、前記VLが、L42にCysを含むか、
xxviii.前記VHが、H43にCysを含み、前記VLが、L45にCysを含むか、
xxix.前記VHが、H43にCysを含み、前記VLが、L102にCysを含むか、
xxx.前記VHが、H46にCysを含み、前記VLが、L3にCysを含むか、
xxxi.前記VHがH46にCysを含み、前記VLが、L5にCysを含むか、
xxxii.前記VHが、H46にCysを含み、前記VLが、L39にCysを含むか、
xxxiii.前記VHが、H46にCysを含み、前記VLが、L42にCysを含むか、
xxxiv.前記VHが、H46にCysを含み、前記VLが、L45にCysを含むか、
xxxv.前記VHが、H46にCysを含み、前記VLが、L100にCysを含むか、
xxxvi.前記VHが、H46にCysを含み、前記VLが、L102にCysを含むか、
xxxvii.前記VHが、H105にCysを含み、前記VLが、L3でCysを含むか、
xxxviii.前記VHが、H105にCysを含み、前記VLが、L5にCysを含むか、
xxxix.前記VHが、H105にCysを含み、前記VLが、L39にCysを含むか、
xl.前記VHが、H105にCysを含み、前記VLが、L45にCysを含むか、
xli.前記VHが、H105にCysを含み、前記VLが、L100にCysを含むか、又は
xlii.前記VHが、H105にCysを含み、前記VLが、L102にCysを含み、
残基番号付けが、Chothiaに従う、提供することと、
b)前記Lが、配列番号2、3、4、5、6、又は7のアミノ酸配列を含むことと、
c)宿主細胞内で前記ポリヌクレオチドを発現させて、前記安定化scFvを産生することと、を含む、プロセス。
[103] 前記宿主細胞が、原核細胞である、上記[102]に記載の方法。
[104] 前記宿主細胞が、真核細胞である、上記[102]に記載の方法。
[105] 重鎖可変領域(VH)と、連結(L)のための手段と、軽鎖可変領域(VL)と、を含む単離された単鎖可変断片(scFv)であって、前記scFvが、
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、scFv。
[106] 抗原結合のための手段と、リンカー(L)と、軽鎖可変領域(VL)と、を含む単離された単鎖可変断片(scFv)であって、前記scFvが、
a)構造的に保存された表面露出抗原結合手段システイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出抗原結合手段Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、scFv。
[107] 重鎖可変領域(VH)と、リンカー(L)と、抗原結合のための手段と、を含む単離された単鎖可変断片(scFv)であって、前記scFvが、
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出抗原結合手段Cysと、第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出抗原結合手段Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、scFv。
[108] 重鎖可変領域(VH)と、連結(L)のための手段と、軽鎖可変領域(VL)と、を含む単鎖可変断片(scFv)を含む多重特異性分子であって、前記scFvが、
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、多重特異性分子。
[109] 抗原結合のための手段と、リンカー(L)と、軽鎖可変領域(VL)と、を含む単鎖可変断片(scFv)を含む多重特異性分子であって、前記scFvが、
a)構造的に保存された表面露出抗原結合手段システイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出抗原結合手段システインCysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、多重特異性分子。
[110] 重鎖可変領域(VH)と、リンカー(L)と、抗原結合(VL)のための手段と、を含む単鎖可変断片(scFv)を含む多重特異性分子であって、前記scFvが、
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出抗原結合手段Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出抗原結合手段Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合と、を含む、多重特異性分子。
[111] 重鎖可変領域(VH)と、連結のための手段(L)と、軽鎖可変領域(VL)と、を含む単鎖可変断片(scFv)を含む異種分子であって、前記scFvが、
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、異種分子。
[112] 抗原結合のための手段と、リンカー(L)と、軽鎖可変領域(VL)と、を含む単鎖可変断片(scFv)を含む異種分子であって、前記scFvが、
a)構造的に保存された表面露出抗原結合手段システイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出抗原結合手段Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、異種分子。
[113] 重鎖可変領域(VH)と、リンカー(L)と、抗原結合のための手段と、を含む単鎖可変断片(scFv)を含む異種分子であって、前記scFvが、
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出抗原結合手段Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出抗原結合手段Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、異種分子。
[114] 上記[105]~[113]のいずれか一項に記載のscFvをコードするための手段。
[115] 前記114のベクターを複製するための手段。
[116] scFvを安定化するための手段を含む組成物。
[117] scFvの熱安定性を増加させるための手段を含む組成物。
[118] 前記手段が、VHとLとの間、VLと前記Lとの間、又は前記VHと前記Lとの間及び前記VLと前記Lとの間にジスルフィド結合を形成することを含む、上記[116]又は[117]に記載の組成物。
[119] scFvを安定化するための手段を含む多重特異性分子。
[120] scFvの熱安定性を増加させるための手段を含む多重特異性分子。
[121] 前記手段が、VHとLとの間、VLと前記Lとの間、又は前記VHと前記Lとの間及び前記VLと前記Lとの間にジスルフィド結合を形成することを含む、上記[119]又は[120]に記載の多重特異性分子。
[122] scFvを安定化するための手段を含む異種分子。
[123] scFvの熱安定性を増加させるための手段を含む異種分子。
[124] 前記手段が、VHとLとの間、VLと前記Lとの間、又は前記VHと前記Lとの間及び前記VLと前記Lとの間にジスルフィド結合を形成することを含む、上記[122]又は[123]に記載の異種分子。
[125] 上記[116]~[118]のいずれか一項に記載の組成物を産生するための手段。
[126] 上記[119]~[121]のいずれか一項に記載の多重特異性分子を産生するための手段。
[127] 上記[122]~[124]のいずれか一項に記載の異種分子を産生するための手段。
This example demonstrates that approaches to activating the LTBR via the multispecific binding molecules provided herein, e.g., binding to both extracellular matrix-associated LTBR and tumor-associated antigens, can be further tested. demonstrated that it functions against all three different tumor-associated antigens of the extracellular matrix that has been developed and is therefore generally applicable to tumor-associated antigens present in the extracellular matrix. This example also demonstrated that molecules incorporating spFv were functional.
The following aspects may be included.
[1] An isolated single-chain variable fragment (scFv) comprising a heavy chain variable region (VH), a linker (L) and a light chain variable region (VL),
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or
c) said first disulfide bond between said structurally conserved surface-exposed VH Cys and said first L Cys, and said structurally conserved surface-exposed VL Cys and said second L Cys; the second disulfide bond between the scFv.
[2] an isolated scFv comprising VH, L and VL,
a) said VH comprises a VH Cys at a structurally conserved surface-exposed VH framework residue position and said L comprises a first L Cys;
b) said VL comprises a VL Cys at a structurally conserved surface-exposed VL framework residue position and said L comprises a second L Cys, or
c) said VH comprises said VH Cys at structurally conserved surface-exposed VH framework residue positions and said VL comprises said VL Cys at structurally conserved surface-exposed VL framework residue positions; wherein said L comprises said first L Cys and said second L Cys, said VH Cys and said first L Cys are capable of forming a disulfide bond, said VL Cys and said second of the L Cys is capable of forming a disulfide bond.
[3] The scFv of [1] or [2] above, wherein the distance between the VH Cys and the VL Cys is about 7 Å to about 9 Å.
[4] The scFv of any one of [1] to [3] above, wherein the VH Cys is at H3, H5, H40, H43, H46 or H105, and residue numbering is according to Chothia.
[5] The scFv of any one of [1] to [4] above, wherein the VL Cys is at L3, L5, L39, L42, L45, L100 or L102, and residue numbering is according to Chothia. .
[6] a) said VH Cys is in H105 and said VL Cys is in L42;
b) said VH Cys is in H43 and said VL Cys is in L100;
c) said VH Cys is in H3 and said VL Cys is in L3;
d) said VH Cys is in H3 and said VL Cys is in L5;
e) said VH Cys is in H3 and said VL Cys is in L39;
f) said VH Cys is in H3 and said VL Cys is in L42;
g) said VH Cys is in H3 and said VL Cys is in L45;
h) said VH Cys is in H3 and said VL Cys is in L100;
i) said VH Cys is in H3 and said VL Cys is in L102;
j) said VH Cys is in H5 and said VL Cys is in L3;
k) said VH Cys is in H5 and said VL Cys is in L5;
l) said VH Cys is in H5 and said VL Cys is in L39;
m) said VH Cys is in H5 and said VL Cys is in L42;
n) said VH Cys is in H5 and said VL Cys is in L45;
o) said VH Cys is in H5 and said VL Cys is in L100;
p) said VH Cys is in H5 and said VL Cys is in L102;
q) said VH Cys is in H40 and said VL Cys is in L3;
r) said VH Cys is in H40 and said VL Cys is in L5;
s) said VH Cys is in H40 and said VL Cys is in L39;
t) said VH Cys is in H40 and said VL Cys is in L42;
u) said VH Cys is in H40 and said VL Cys is in L45;
v) said VH Cys is in H40 and said VL Cys is in L100;
w) said VH Cys is in H40 and said VL Cys is in L102;
x) said VH Cys is in H43 and said VL Cys is in L3;
y) said VH Cys is in H43 and said VL Cys is in L5;
z) said VH Cys is at H43 and said VL Cys is at L39;
aa) said VH Cys is in H43 and said VL Cys is in L42;
bb) said VH Cys is in H43 and said VL Cys is in L45;
cc) said VH Cys is in H43 and said VL Cys is in L102;
dd) said VH Cys is in H46 and said VL Cys is in L3;
ee) said VH Cys is in H46 and said VL Cys is in L5;
ff) said VH Cys is in H46 and said VL Cys is in L39;
gg) said VH Cys is in H46 and said VL Cys is in L42;
hh) said VH Cys is in H46 and said VL Cys is in L45;
ii) said VH Cys is in H46 and said VL Cys is in L100;
jj) said VH Cys is in H46 and said VL Cys is in L102;
kk) said VH Cys is in H105 and said VL Cys is in L3;
ll) said VH Cys is in H105 and said VL Cys is in L5;
mm) said VH Cys is in H105 and said VL Cys is in L39;
nn) said VH Cys is in H105 and said VL Cys is in L45;
oo) said VH Cys is in H105 and said VL Cys is in L100, or
pp) The scFv of any one of [1] to [5] above, wherein said VH Cys is at H105, said VL Cys is at L102, and residue numbering is according to Chothia.
[7] The scFv of any one of [1] to [6] above, wherein said L comprises a contiguous amino acid sequence derived from an immunoglobulin (Ig) hinge region.
[8] The scFv of [7] above, wherein the Ig hinge region is derived from a human or non-human Ig hinge region.
[9] The scFv of [8] above, wherein the Ig hinge region is derived from the human Ig hinge region.
[10] The scFv of [9] above, wherein the human Ig hinge region is of the IgG1, IgG2, IgG3 or IgG4 isotype.
[11] L comprises the amino acid sequence C(X) y C (SEQ ID NO: 23), wherein X is glycine (Gly), serine (Ser), proline (Pro), alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), glutamic acid (GIu), glutamine (Gln), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), phenylalanine (Phe), The scFv according to any one of [1] to [10] above, which is threonine (Thr), tryptophan (Trp), or tyrosine (Tyr), and y is an integer of 1-3.
[12] The above [ 11].
[13] L is the amino acid sequence CPC, CGC, CSC, CPPC (SEQ ID NO: 1), CGPC (SEQ ID NO: 28), CPGC (SEQ ID NO: 29), CGGC (SEQ ID NO: 30), CSPG (SEQ ID NO: 31) , CPSC (SEQ ID NO: 32), CSSC (SEQ ID NO: 33), CGSC (SEQ ID NO: 34), CSGC (SEQ ID NO: 35), CPPPC (SEQ ID NO: 36), CGPPC (SEQ ID NO: 37), CGPPC (SEQ ID NO: 38), CPPGC (SEQ ID NO: 39), CGGPC (SEQ ID NO: 40), CPGGC (SEQ ID NO: 41), CGGGC (SEQ ID NO: 42), CSPPC (SEQ ID NO: 43), CPSPC (SEQ ID NO: 44), CPPSC (SEQ ID NO: 45), CSSPC (SEQ ID NO: 46), CPSSC (SEQ ID NO: 47), CSSSC (SEQ ID NO: 48), CGSPC (SEQ ID NO: 49), CPGSC (SEQ ID NO: 50), CSGPC (SEQ ID NO: 51) or CPSGC (SEQ ID NO: 52); The scFv according to any one of [1] to [12] above.
[14] Any one of [1] to [13] above, wherein L comprises about 14 to about 19 amino acids, for example, about 14, about 15, about 16, about 17, about 18, or about 19 amino acids The scFv described in section.
[15] said L comprises the amino acid sequence (X) m C(X) y C(X) n (SEQ ID NO: 25), wherein X is Gly, Ser, Pro, Ala, Arg, Asn, Asp , Glu, Gln, His, Ile, leu, Lys, Phe, Thr, Trp or Tyr, m is an integer of 6 to 9, y is an integer of 1 to 3, n is 4 to The scFv according to any one of [1] to [14] above, which is an integer of 6.
[16] said L comprises the amino acid sequence (X) m C(X) y C(X) n (SEQ ID NO: 26), wherein X is Gly, Ser, Pro, Ala, Arg, Asn, Asp , Glu, Gln, His, Ile, Leu, Lys, Thr or Tyr, m is an integer of 6 to 9, y is an integer of 1 to 3, n is an integer of 4 to 6 The scFv according to [15] above.
[17] said L comprises the amino acid sequence (X) m C(X) y C(X) n (SEQ ID NO: 27), wherein X is Gly or Pro, m is 6-9 The scFv according to [16] above, which is an integer, y is an integer of 1-3, and n is an integer of 4-6.
[18] The scFv of any one of [1] to [17] above, wherein said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7.
[19] The scFv of any one of [1] to [18] above, wherein the scFv is in the VL-L-VH orientation.
[20] The scFv of any one of [1] to [18] above, wherein the scFv is in the VH-L-VL orientation.
[21] a scFv comprising VH, L, and VL,
a) said VH contains Cys in H105,
b) said VL contains Cys at L42;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VL-L-VH orientation.
[22] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H105,
b) said VL contains Cys at L45;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VL-L-VH orientation.
[23] a scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H105,
b) said VL contains Cys at L39;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VL-L-VH orientation.
[24] a scFv comprising VH, L, and VL,
a) said VH contains Cys in H5,
b) said VL contains Cys at L42;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VL-L-VH orientation.
[25] a scFv comprising VH, L, and VL,
a) said VH contains Cys in H5,
b) said VL contains Cys at L45;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VL-L-VH orientation.
[26] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H5,
b) said VL contains Cys at L39;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VL-L-VH orientation.
[27] a scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H3,
b) said VL contains Cys at L42;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VL-L-VH orientation.
[28] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H3,
b) said VL contains Cys at L45;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VL-L-VH orientation.
[29] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H3,
b) said VL contains Cys at L39;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VL-L-VH orientation.
[30] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H43,
b) said VL contains Cys in L100,
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[31] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H43,
b) said VL contains Cys at L102;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[32] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H43,
b) said VL comprises Cys in L5,
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[33] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H43,
b) said VL contains Cys in L3,
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[34] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H40,
b) said VL contains Cys in L100,
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[35] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H40,
b) said VL contains Cys at L102;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[36] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H40,
b) said VL comprises Cys in L5,
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[37] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H40,
b) said VL contains Cys in L3,
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[38] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H46,
b) said VL contains Cys in L100,
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[39] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H46,
b) said VL contains Cys at L102;
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[40] a scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H46,
b) said VL comprises Cys in L5,
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[41] A scFv comprising VH, L, and VL, wherein
a) said VH contains Cys in H46,
b) said VL contains Cys in L3,
c) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7;
d) scFv, wherein said scFv is in the VH-L-VL orientation.
[42] The scFv of any one of [21] to [41] above, wherein said L comprises the amino acid sequence of SEQ ID NO:3.
[43] The scFv of any one of [21] to [41] above, wherein said L comprises the amino acid sequence of SEQ ID NO:6.
[44] The scFv of any one of [21] to [41] above, wherein said L comprises the amino acid sequence of SEQ ID NO:7.
[45] The scFv of any one of [1] to [44] above, wherein the scFv is conjugated to a second molecule.
[46] The scFv of [45] above, wherein the second molecule is a half-life extending moiety.
[47] The above-described [ 46].
[48] The scFv of [45] above, wherein the second molecule is a cytotoxic agent or a detectable label.
[49] The scFv of [48] above, wherein the second molecule is an antibody or fragment thereof.
[50] The scFv of [49] above, wherein the scFv and the antibody or fragment thereof bind to different antigens.
[51] The scFv of [45] above, wherein the second molecule is a chimeric antigen receptor (CAR).
[52] A pharmaceutical composition comprising the scFv of any one of [1] to [51] above and a pharmaceutically acceptable carrier.
[53] A polynucleotide that encodes the scFv of any one of [1] to [44] above.
[54] A vector comprising the polynucleotide of [53] above.
[55] A host cell containing the vector of [54] above.
[56] A method for producing the scFv of any one of [1] to [44] above, comprising culturing the host cell of [55] above under conditions for producing the scFv; and purifying said scFv.
[57] The method of [56] above, wherein the host cell is a prokaryotic cell.
[58] The method of [56] above, wherein the host cell is a eukaryotic cell.
[59] An anti-idiotypic antibody that binds to the scFv of any one of [1] to [44] above.
[60] A kit comprising the scFv of any one of [1] to [44] above.
[61] A multispecific molecule comprising the scFv of any one of [1] to [44] above.
[62] The multispecific molecule of [61] above, wherein the multispecific molecule comprises an antibody or antibody fragment.
[63] The multispecific molecule of [61] above, wherein the multispecific protein comprises an Ig constant region or a fragment of the Ig constant region.
[64] The multispecific protein of [63] above, wherein the fragment of the Ig constant region comprises an Fc region.
[65] The multispecific molecule of [63] above, wherein said fragment of said Ig constant region comprises a CH2 domain.
[66] The multispecific molecule of [63] above, wherein said fragment of said Ig constant region comprises a CH3 domain.
[67] The multispecific molecule of [63] above, wherein said fragment of said Ig constant region comprises said CH2 domain and said CH3 domain.
[68] The multispecific molecule of [63] above, wherein said fragment of said Ig constant region comprises at least a portion of a hinge, said CH2 domain and said CH3 domain.
[69] The multispecific molecule of [63] above, wherein said fragment of said Ig constant region comprises said hinge, said CH2 domain, and said CH3 domain.
[70] The multispecific molecule of any one of [63] to [69] above, wherein said scFv is conjugated to the N-terminus of said Ig constant region or the N-terminus of said fragment of said Ig constant region. .
[71] The multispecific molecule according to any one of [63] to [69] above, wherein the scFv is conjugated to the C-terminus of the Ig constant region or the N-terminus of the fragment of the Ig constant region. .
[72] The multispecific molecule according to any one of [63] to [71] above, wherein the Ig constant region or the fragment of the Ig constant region is of IgG1, IgG2, and IgG3 or IgG4 isotypes.
[73] Any one of [63] to [72] above, wherein said Ig constant region or said fragment of said Ig constant region comprises at least one mutation that reduces binding of said multispecific molecule to FcγR A multispecific molecule as described in .
[74] said at least one mutation that reduces binding of said multispecific molecule to an FcγR is selected from , F234A/L235A, S228P/F234A/L235A, N297A, V234A/G237A, K214T/E233P/L234V/L235A/G236-deletion/A327G/P331A/D365E/L358M, H268Q/V309L/A330 S/P331S, S267E/L328F, L234F/L235E/D265A, L234A/L235A/G237A/P238S/H268A/A330S/P331S, S228P/F234A/L235A/G237A/P238S and S228P/F234A/L235A/G236-deletion/G237A /P238S selected from the group consisting of , the multispecific molecule according to [73] above, wherein residue numbering is according to the EU index.
[75] Any one of [63] to [72] above, wherein the Ig constant region or the fragment of the Ig constant region comprises at least one mutation that enhances binding of the multispecific molecule to FcγR A multispecific molecule as described in .
[76] the at least one mutation that enhances binding of the multispecific molecule to an FcγR is /Y300L/V305I/P396L and G236A/S239D/I332E, wherein residue numbering is according to the EU index, according to [75] above.
[77] The multispecific molecule of any one of [73] to [76] above, wherein the FcγR is FcγRI, FcγRIIA, FcγRIIB, or FcγRIII, or any combination thereof.
[78] Any one of [63] to [72] above, wherein the Ig constant region or fragment of the Ig constant region comprises at least one mutation that modulates the half-life of the multispecific molecule. Multispecific molecule.
[79] the group wherein said at least one mutation that modulates said half-life of said multispecific molecule consists of H435A, P257I/N434H, D376V/N434H, M252Y/S254T/T256E/H433K/N434F, T308P/N434A and H435R and wherein residue numbering is according to the EU index, according to [78] above.
[80] The multispecific molecule of any one of [63]-[72] above, wherein said Ig constant region or fragment of said Ig constant region comprises at least one mutation in said CH3 domain.
[81] wherein said at least one mutation in said CH3 domain is I/ K392M/T394W, F405A/Y407V, T366L/K392M/T394W, L351Y/Y407A, T366A/K409F, L351Y/Y407A, T366V/K409F, T366A/K409F, T350V/L351Y/F405A/Y from 407V and T350V/T366L/K392L/T394W The multispecific molecule according to [80] above, wherein the residue numbering is according to the EU index.
[82] The multispecific molecule according to any one of [61] to [81] above, wherein the multispecific molecule is bispecific.
[83] The multispecific molecule of any one of [61] to [81] above, wherein the multispecific molecule is trispecific.
[84] The multispecific molecule according to any one of [61] to [81] above, wherein the multispecific molecule is tetraspecific.
[85] A pharmaceutical composition comprising the multispecific molecule of any one of [61] to [84] above and a pharmaceutically acceptable carrier.
[86] A heterologous molecule comprising the scFv of any one of [1] to [44] above.
[87] The heterologous molecule of [86] above, wherein said scFv is conjugated to a second protein, polynucleotide, therapeutic agent, cytotoxic agent or detectable label.
[88] The heterologous molecule of [87] above, wherein the second protein is an antibody or fragment thereof.
[89] The heterologous molecule of [87] above, wherein said second protein is an alternative scaffold.
[90] The heterologous molecule of [87] above, wherein said second protein is a chimeric antigen receptor (CAR) or a fragment thereof.
[91] The heterologous molecule of any one of [86] to [90] above, wherein the heterologous molecule is monospecific.
[92] The heterologous molecule of any one of [86] to [90] above, wherein the heterologous molecule is multispecific.
[93] The heterologous molecule of [92] above, wherein the heterologous molecule is bispecific.
[94] The heterologous molecule of [92] above, wherein the heterologous molecule is trispecific.
[95] The heterologous molecule of [92] above, wherein the heterologous molecule is quadraspecific.
[96] A pharmaceutical composition comprising the heterologous molecule of any one of [86] to [95] above and a pharmaceutically acceptable carrier.
[97] A process for preparing a stabilized scFv comprising:
providing a heavy chain variable region (VH) and a light chain variable region (VL) that form an antigen binding domain;
providing a linker (L) comprising or engineered to comprise the first L Cys;
engineering said VH to include VH Cys at structurally conserved surface-exposed VH framework residue positions;
forming a disulfide bond between said VH Cys and said first L Cys to prepare said stabilized scFv.
[98] A process for preparing a stabilized scFv comprising:
providing VH and VL that form an antigen binding domain;
providing L containing or engineered to contain a second L Cys;
engineering said VL to include VL Cys at structurally conserved surface-exposed VL framework residue positions;
forming a disulfide bond between said VL Cys and said second L Cys to prepare said stabilized scFv.
[99] A process for preparing a stabilized scFv comprising:
providing VH and VL that form an antigen binding domain;
providing L comprising or engineered to comprise a first L Cys and a second L Cys;
engineering said VH to include VH Cys at structurally conserved, surface-exposed VH framework residue positions;
engineering said VL to include VL Cys at structurally conserved surface-exposed VL framework residue positions;
forming a disulfide bond between the VH Cys and the first L Cys and a disulfide bond between the VL Cys and the second L Cys to prepare the stabilized scFv; , including the process.
[100] The process of any one of [97] to [99] above, wherein the stabilized scFv is the scFv of any one of [1] to [44] above.
[101] The process of any one of [97]-[100] above, wherein said stabilized scFv binds antigen with comparable affinity when compared to a control scFv lacking said disulfide bond. .
[102] A process for preparing a stabilized scFv comprising:
a) providing polynucleotides encoding VH, L and VL,
i. said VH comprises Cys at H105 and said VL comprises Cys at L42;
ii. said VH comprises Cys at H43 and said VL comprises Cys at L100;
iii. said VH comprises Cys in H3 and said VL comprises Cys in L3;
iv. said VH comprises Cys at H3 and said VL comprises Cys at L5;
v. said VH comprises Cys at H3 and said VL comprises Cys at L39;
vi. said VH comprises Cys at H3 and said VL comprises Cys at L42;
vii. said VH comprises Cys at H3 and said VL comprises Cys at L45;
viii. said VH comprises Cys in H3 and said VL comprises Cys in L100;
ix. said VH comprises Cys at H3 and said VL comprises Cys at L102;
x. said VH comprises Cys at H5 and said VL comprises Cys at L3;
xi. said VH comprises Cys at H5 and said VL comprises Cys at L5;
xii. said VH comprises Cys at H5 and said VL comprises Cys at L39;
xiii. said VH comprises Cys at H5 and said VL comprises Cys at L42;
xiv. said VH comprises Cys at H5 and said VL comprises Cys at L45;
xv. said VH comprises Cys at H5 and said VL comprises Cys at L100;
xvi. said VH comprises Cys at H5 and said VL comprises Cys at L102;
xvii. said VH comprises Cys at H40 and said VL comprises Cys at L3;
xviii. said VH comprises Cys at H40 and said VL comprises Cys at L5;
xix. said VH comprises Cys at H40 and said VL comprises Cys at L39;
xx. said VH comprises Cys at H40 and said VL comprises Cys at L42;
xxi. said VH comprises iCys in H40 and said VL comprises Cys in L45;
xxii. said VH comprises Cys in H40 and said VL comprises Cys in L100;
xxiii. said VH comprises Cys at H40 and said VL comprises Cys at L102;
xxiv. said VH comprises Cys at H43 and said VL comprises Cys at L3;
xxv. said VH comprises Cys at H43 and said VL comprises Cys at L5;
xxvi. said VH comprises Cys at H43 and said VL comprises Cys at L39;
xxvii. said VH comprises Cys at H43 and said VL comprises Cys at L42;
xxviii. said VH comprises Cys at H43 and said VL comprises Cys at L45;
xxix. said VH comprises Cys at H43 and said VL comprises Cys at L102;
xxx. said VH comprises Cys at H46 and said VL comprises Cys at L3;
xxxi. said VH comprises Cys at H46 and said VL comprises Cys at L5;
xxxii. said VH comprises Cys at H46 and said VL comprises Cys at L39;
xxxiii. said VH comprises Cys at H46 and said VL comprises Cys at L42;
xxxiv. said VH comprises Cys at H46 and said VL comprises Cys at L45;
xxxv. said VH comprises Cys at H46 and said VL comprises Cys at L100;
xxxvi. said VH comprises Cys at H46 and said VL comprises Cys at L102;
xxxvii. said VH comprises Cys at H105 and said VL comprises Cys at L3;
xxxviii. said VH comprises Cys at H105 and said VL comprises Cys at L5;
xxxix. said VH comprises Cys at H105 and said VL comprises Cys at L39;
xl. said VH comprises Cys at H105 and said VL comprises Cys at L45;
xli. said VH comprises Cys at H105 and said VL comprises Cys at L100, or
xli. the VH contains Cys at H105, the VL contains Cys at L102,
providing residue numbering according to Chothia;
b) said L comprises the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6, or 7;
c) expressing said polynucleotide in a host cell to produce said stabilized scFv.
[103] The method of [102] above, wherein the host cell is a prokaryotic cell.
[104] The method of [102] above, wherein the host cell is a eukaryotic cell.
[105] An isolated single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a means for joining (L), and a light chain variable region (VL), wherein said scFv but,
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or
c) said first disulfide bond between said structurally conserved surface-exposed VH Cys and said first L Cys and said structurally conserved surface-exposed VL Cys and said second L Cys; the second disulfide bond between
[106] An isolated single chain variable fragment (scFv) comprising means for antigen binding, a linker (L), and a light chain variable region (VL), wherein said scFv comprises
a) the first disulfide bond between the structurally conserved surface-exposed antigen binding means cysteine (Cys) and the first L Cys;
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or
c) said first disulfide bond between said structurally conserved surface-exposed antigen binding means Cys and said first L Cys and said structurally conserved surface-exposed VL Cys and said second L said second disulfide bond with Cys.
[107] An isolated single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a linker (L), and a means for antigen binding, said scFv comprising:
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between the structurally conserved surface-exposed antigen binding means Cys and the second L Cys, or
c) said first disulfide bond between said structurally conserved surface exposed VH Cys and said first L Cys and said structurally conserved surface exposed antigen binding means Cys and said second L said second disulfide bond with Cys.
[108] A multispecific molecule comprising a single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a means for joining (L), and a light chain variable region (VL), wherein The scFv is
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or
c) said first disulfide bond between said structurally conserved surface-exposed VH Cys and said first L Cys and said structurally conserved surface-exposed VL Cys and said second L Cys; said second disulfide bond between
[109] A multispecific molecule comprising a single chain variable fragment (scFv) comprising means for antigen binding, a linker (L), and a light chain variable region (VL), wherein said scFv is
a) the first disulfide bond between the structurally conserved surface-exposed antigen binding means cysteine (Cys) and the first L Cys;
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or
c) said first disulfide bond between said structurally conserved surface-exposed antigen binding means Cysteine Cys and said first L Cys and said structurally conserved surface-exposed VL Cys and said second said second disulfide bond with L Cys.
[110] A multispecific molecule comprising a single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a linker (L), and means for antigen binding (VL), wherein said scFv but,
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between the structurally conserved surface-exposed antigen binding means Cys and the second L Cys, or
c) said first disulfide bond between said structurally conserved surface exposed VH Cys and said first L Cys and said structurally conserved surface exposed antigen binding means Cys and said second L and said second disulfide bond with Cys.
[111] A heterologous molecule comprising a single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a means for linking (L), and a light chain variable region (VL), wherein said scFv but,
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or
c) said first disulfide bond between said structurally conserved surface-exposed VH Cys and said first L Cys and said structurally conserved surface-exposed VL Cys and said second L Cys; said second disulfide bond between
[112] A heterologous molecule comprising a single chain variable fragment (scFv) comprising means for antigen binding, a linker (L), and a light chain variable region (VL), wherein said scFv comprises
a) the first disulfide bond between the structurally conserved surface-exposed antigen binding means cysteine (Cys) and the first L Cys;
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or
c) said first disulfide bond between said structurally conserved surface-exposed antigen binding means Cys and said first L Cys and said structurally conserved surface-exposed VL Cys and said second L said second disulfide bond with Cys.
[113] A heterologous molecule comprising a single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a linker (L), and means for antigen binding, wherein said scFv is
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between the structurally conserved surface-exposed antigen binding means Cys and the second L Cys, or
c) said first disulfide bond between said structurally conserved surface exposed VH Cys and said first L Cys and said structurally conserved surface exposed antigen binding means Cys and said second L said second disulfide bond with Cys.
[114] A means for encoding the scFv of any one of [105] to [113] above.
[115] A means for replicating the vector of 114 above.
[116] A composition comprising a means for stabilizing a scFv.
[117] A composition comprising a means for increasing the thermostability of a scFv.
[118] said means comprises forming a disulfide bond between VH and L, between VL and said L, or between said VH and said L and between said VL and said L; The composition according to [116] or [117] above.
[119] Multispecific molecules comprising means for stabilizing scFv.
[120] Multispecific molecules comprising means for increasing the thermostability of scFv.
[121] said means comprises forming a disulfide bond between VH and L, between VL and said L, or between said VH and said L and between said VL and said L; The multispecific molecule of [119] or [120] above.
[122] Heterologous molecules comprising means for stabilizing scFv.
[123] Heterologous molecules, including means for increasing the thermostability of scFv.
[124] said means comprises forming a disulfide bond between VH and L, between VL and said L, or between said VH and said L and between said VL and said L; The heterologous molecule of [122] or [123] above.
[125] A means for producing the composition of any one of [116] to [118] above.
[126] A means for producing the multispecific molecule of any one of [119] to [121] above.
[127] A means for producing the heterologous molecule of any one of [122] to [124] above.
Claims (77)
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合、及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、scFv。 An isolated single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a linker (L) and a light chain variable region (VL),
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between the structurally conserved surface-exposed VL Cys and the second L Cys, or c) said structurally conserved surface-exposed VH Cys and said first L Cys. and said second disulfide bond between said structurally conserved surface-exposed VL Cys and said second L Cys.
a)前記VHが、構造的に保存された表面露出VHフレームワーク残基位置にVH Cysを含み、前記Lが、第1のL Cysを含むか、
b)前記VLが、構造的に保存された表面露出VLフレームワーク残基位置にVL Cysを含み、前記Lが、第2のL Cysを含むか、又は
c)前記VHが、構造的に保存された表面露出VHフレームワーク残基位置に前記VH Cysを含み、前記VLが、構造的に保存された表面露出VLフレームワーク残基位置に前記VL Cysを含み、前記Lが、前記第1のL Cys及び前記第2のL Cysを含み、前記VH Cys及び前記第1のL Cysが、ジスルフィド結合を形成することができ、前記VL Cys及び前記第2のL Cysが、ジスルフィド結合を形成することができる、単離されたscFv。 An isolated scFv comprising VH, L and VL,
a) said VH comprises a VH Cys at a structurally conserved surface-exposed VH framework residue position and said L comprises a first L Cys;
b) said VL comprises a VL Cys at a structurally conserved surface-exposed VL framework residue position and said L comprises a second L Cys, or c) said VH is structurally conserved said VH Cys at surface-exposed VH framework residue positions, said VL comprising said VL Cys at structurally conserved surface-exposed VL framework residue positions, said L comprising L Cys and said second L Cys, wherein said VH Cys and said first L Cys are capable of forming a disulfide bond, and said VL Cys and said second L Cys form a disulfide bond An isolated scFv that can be.
前記VL Cysが、L3、L5、L39、L42、L45、L100又はL102にあり、残基番号付けは、Chothiaに従う、
請求項1~3のいずれか一項に記載のscFv。 said VH Cys is at H3, H5, H40, H43, H46 or H105 and residue numbering is according to Chothia; and/or
the VL Cys is at L3, L5, L39, L42, L45, L100 or L102 and residue numbering is according to Chothia;
The scFv of any one of claims 1-3.
b)前記VH CysがH43にあり、前記VL CysがL100にあるか、
c)前記VH CysがH3にあり、前記VL CysがL3にあるか、
d)前記VH CysがH3にあり、前記VL CysがL5にあるか、
e)前記VH CysがH3にあり、前記VL CysがL39にあるか、
f)前記VH CysがH3にあり、前記VL CysがL42にあるか、
g)前記VH CysがH3にあり、前記VL CysがL45にあるか、
h)前記VH CysがH3にあり、前記VL CysがL100にあるか、
i)前記VH CysがH3にあり、前記VL CysがL102にあるか、
j)前記VH CysがH5にあり、前記VL CysがL3にあるか、
k)前記VH CysがH5にあり、前記VL CysがL5にあるか、
l)前記VH CysがH5にあり、前記VL CysがL39にあるか、
m)前記VH CysがH5にあり、前記VL CysがL42にあるか、
n)前記VH CysがH5にあり、前記VL CysがL45にあるか、
o)前記VH CysがH5にあり、前記VL CysがL100にあるか、
p)前記VH CysがH5にあり、前記VL CysがL102にあるか、
q)前記VH CysがH40にあり、前記VL CysがL3にあるか、
r)前記VH CysがH40にあり、前記VL CysがL5にあるか、
s)前記VH CysがH40にあり、前記VL CysがL39にあるか、
t)前記VH CysがH40にあり、前記VL CysがL42にあるか、
u)前記VH CysがH40にあり、前記VL CysがL45にあるか、
v)前記VH CysがH40にあり、前記VL CysがL100にあるか、
w)前記VH CysがH40にあり、前記VL CysがL102にあるか、
x)前記VH CysがH43にあり、前記VL CysがL3にあるか、
y)前記VH CysがH43にあり、前記VL CysがL5にあるか、
z)前記VH CysがH43にあり、前記VL CysがL39にあるか、
aa)前記VH CysがH43にあり、前記VL CysがL42にあるか、
bb)前記VH CysがH43にあり、前記VL CysがL45にあるか、
cc)前記VH CysがH43にあり、前記VL CysがL102にあるか、
dd)前記VH CysがH46にあり、前記VL CysがL3にあるか、
ee)前記VH CysがH46にあり、前記VL CysがL5にあるか、
ff)前記VH CysがH46にあり、前記VL CysがL39にあるか、
gg)前記VH CysがH46にあり、前記VL CysがL42にあるか、
hh)前記VH CysがH46にあり、前記VL CysがL45にあるか、
ii)前記VH CysがH46にあり、前記VL CysがL100にあるか、
jj)前記VH CysがH46にあり、前記VL CysがL102にあるか、
kk)前記VH CysがH105にあり、前記VL CysがL3にあるか、
ll)前記VH CysがH105にあり、前記VL CysがL5にあるか、
mm)前記VH CysがH105にあり、前記VL CysがL39にあるか、
nn)前記VH CysがH105にあり、前記VL CysがL45にあるか、
oo)前記VH CysがH105にあり、前記VL CysがL100にあるか、又は
pp)前記VH CysがH105にあり、前記VL CysがL102にあり、残基番号付けがChothiaに従う、請求項1~4のいずれか一項に記載のscFv。 a) said VH Cys is in H105 and said VL Cys is in L42;
b) said VH Cys is in H43 and said VL Cys is in L100;
c) said VH Cys is in H3 and said VL Cys is in L3;
d) said VH Cys is in H3 and said VL Cys is in L5;
e) said VH Cys is in H3 and said VL Cys is in L39;
f) said VH Cys is in H3 and said VL Cys is in L42;
g) said VH Cys is in H3 and said VL Cys is in L45;
h) said VH Cys is in H3 and said VL Cys is in L100;
i) said VH Cys is in H3 and said VL Cys is in L102;
j) said VH Cys is in H5 and said VL Cys is in L3;
k) said VH Cys is in H5 and said VL Cys is in L5;
l) said VH Cys is in H5 and said VL Cys is in L39;
m) said VH Cys is in H5 and said VL Cys is in L42;
n) said VH Cys is in H5 and said VL Cys is in L45;
o) said VH Cys is in H5 and said VL Cys is in L100;
p) said VH Cys is in H5 and said VL Cys is in L102;
q) said VH Cys is in H40 and said VL Cys is in L3;
r) said VH Cys is in H40 and said VL Cys is in L5;
s) said VH Cys is in H40 and said VL Cys is in L39;
t) said VH Cys is in H40 and said VL Cys is in L42;
u) said VH Cys is in H40 and said VL Cys is in L45;
v) said VH Cys is in H40 and said VL Cys is in L100;
w) said VH Cys is in H40 and said VL Cys is in L102;
x) said VH Cys is in H43 and said VL Cys is in L3;
y) said VH Cys is in H43 and said VL Cys is in L5;
z) said VH Cys is at H43 and said VL Cys is at L39;
aa) said VH Cys is in H43 and said VL Cys is in L42;
bb) said VH Cys is in H43 and said VL Cys is in L45;
cc) said VH Cys is in H43 and said VL Cys is in L102;
dd) said VH Cys is in H46 and said VL Cys is in L3;
ee) said VH Cys is in H46 and said VL Cys is in L5;
ff) said VH Cys is in H46 and said VL Cys is in L39;
gg) said VH Cys is in H46 and said VL Cys is in L42;
hh) said VH Cys is in H46 and said VL Cys is in L45;
ii) said VH Cys is in H46 and said VL Cys is in L100;
jj) said VH Cys is in H46 and said VL Cys is in L102;
kk) said VH Cys is in H105 and said VL Cys is in L3;
ll) said VH Cys is in H105 and said VL Cys is in L5;
mm) said VH Cys is in H105 and said VL Cys is in L39;
nn) said VH Cys is in H105 and said VL Cys is in L45;
oo) said VH Cys is at H105 and said VL Cys is at L100, or pp) said VH Cys is at H105 and said VL Cys is at L102, residue numbering according to Chothia. 5. The scFv of any one of 4 .
前記Igヒンジ領域が、前記ヒトIgヒンジ領域に由来するか、又は
前記Igヒンジ領域が、前記ヒトIgヒンジ領域に由来し、前記ヒトIgヒンジ領域が、IgG1、IgG2、IgG3又はIgG4アイソタイプである、
請求項6に記載のscFv。 whether said Ig hinge region is derived from a human or non-human Ig hinge region;
said Ig hinge region is derived from said human Ig hinge region, or
said Ig hinge region is derived from said human Ig hinge region and said human Ig hinge region is of the IgG1, IgG2, IgG3 or IgG4 isotype;
The scFv of claim 6 .
前記Lが、アミノ酸配列C(X) y C(配列番号24)を含み、式中、Xは、Gly、Ser又はProであり、yは、1~3の整数である、
請求項1~7のいずれか一項に記載のscFv。 L comprises the amino acid sequence C(X) y C (SEQ ID NO: 23), wherein X is glycine (Gly), serine (Ser), proline (Pro), alanine (Ala), arginine (Arg) , asparagine (Asn), aspartic acid (Asp), glutamic acid (Glu), glutamine (Gln), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), phenylalanine (Phe), threonine (Thr ), tryptophan (Trp) or tyrosine (Tyr), and y is an integer from 1 to 3, or
wherein L comprises the amino acid sequence C(X) y C (SEQ ID NO: 24), wherein X is Gly, Ser or Pro and y is an integer from 1 to 3;
The scFv of any one of claims 1-7 .
前記Lが、アミノ酸配列(X) m C(X) y C(X) n (配列番号26)を含み、式中、Xは、Gly、Ser、Pro、Ala、Arg、Asn、Asp、Glu、Gln、His、Ile、Leu、Lys、Thr又はTyrであり、mは、6~9の整数であり、yは、1~3の整数であり、nは、4~6の整数である、又は
前記Lが、アミノ酸配列(X) m C(X) y C(X) n (配列番号27)を含み、式中、Xは、Gly又はProであり、mは、6~9の整数であり、yは、1~3の整数であり、nは、4~6の整数である、
請求項1~10のいずれか一項に記載のscFv。 L comprises the amino acid sequence (X) m C(X) y C(X) n (SEQ ID NO: 25), wherein X is Gly, Ser, Pro, Ala, Arg, Asn, Asp, Glu, Gln, His, Ile, leu, Lys, Phe, Thr, Trp or Tyr, m is an integer of 6 to 9, y is an integer of 1 to 3, n is an integer of 4 to 6 is or
L comprises the amino acid sequence (X) m C(X) y C(X) n (SEQ ID NO: 26), wherein X is Gly, Ser, Pro, Ala, Arg, Asn, Asp, Glu, Gln, His, Ile, Leu, Lys, Thr or Tyr, m is an integer from 6 to 9, y is an integer from 1 to 3, and n is an integer from 4 to 6, or
L comprises the amino acid sequence (X) m C(X) y C(X) n (SEQ ID NO: 27), wherein X is Gly or Pro and m is an integer from 6 to 9 , y is an integer from 1 to 3 and n is an integer from 4 to 6;
The scFv of any one of claims 1-10 .
前記scFvが、VH-L-VL配向にある、
請求項1~12のいずれか一項に記載のscFv。 said scFv is in the VL-L-VH orientation, or
said scFv is in the VH-L-VL orientation;
The scFv of any one of claims 1-12 .
(1)a)前記VHが、H105にCysを含み、
b)前記VLが、L42にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にあるか、
(2)a)前記VHが、H105にCysを含み、
b)前記VLが、L45にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にあるか、
(3)a)前記VHが、H105にCysを含み、
b)前記VLが、L39にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にあるか、
(4)a)前記VHが、H5にCysを含み、
b)前記VLが、L42にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にあるか、
(5)a)前記VHが、H5にCysを含み、
b)前記VLが、L45にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にあるか、
(6)a)前記VHが、H5にCysを含み、
b)前記VLが、L39にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にあるか、
(7)a)前記VHが、H3にCysを含み、
b)前記VLが、L42にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にあるか、
(8)a)前記VHが、H3にCysを含み、
b)前記VLが、L45にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にあるか、
(9)a)前記VHが、H3にCysを含み、
b)前記VLが、L39にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VL-L-VH配向にあるか、
(10)a)前記VHが、H43にCysを含み、
b)前記VLが、L100にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(11)a)前記VHが、H43にCysを含み、
b)前記VLが、L102にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(12)a)前記VHが、H43にCysを含み、
b)前記VLが、L5にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(13)a)前記VHが、H43にCysを含み、
b)前記VLが、L3にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(14)a)前記VHが、H40にCysを含み、
b)前記VLが、L100にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(15)a)前記VHが、H40にCysを含み、
b)前記VLが、L102にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(16)a)前記VHが、H40にCysを含み、
b)前記VLが、L5にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(17)a)前記VHが、H40にCysを含み、
b)前記VLが、L3にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(18)a)前記VHが、H46にCysを含み、
b)前記VLが、L100にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(19)a)前記VHが、H46にCysを含み、
b)前記VLが、L102にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、
(20)a)前記VHが、H46にCysを含み、
b)前記VLが、L5にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にあるか、又は
(21)a)前記VHが、H46にCysを含み、
b)前記VLが、L3にCysを含み、
c)前記Lが、配列番号3、4、5、6又は7のアミノ酸配列を含み、
d)前記scFvが、VH-L-VL配向にある、
scFv。 scFv comprising VH, L, and VL,
(1) a) the VH contains Cys in H105,
b) said VL contains Cys at L42;
c) said L comprises the amino acid sequence of SEQ ID NO : 3 , 4, 5, 6 or 7;
d) said scFv is in the VL-L-VH orientation ;
(2) a) the VH contains Cys in H105;
b) said VL contains Cys at L45;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VL-L-VH orientation;
(3) a) the VH contains Cys in H105;
b) said VL contains Cys at L39;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VL-L-VH orientation;
(4) a) the VH contains Cys in H5;
b) said VL contains Cys at L42;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VL-L-VH orientation;
(5) a) the VH contains Cys in H5;
b) said VL contains Cys at L45;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VL-L-VH orientation;
(6) a) the VH contains Cys in H5;
b) said VL contains Cys at L39;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VL-L-VH orientation;
(7) a) the VH contains Cys in H3;
b) said VL contains Cys at L42;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VL-L-VH orientation;
(8) a) the VH contains Cys in H3;
b) said VL contains Cys at L45;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VL-L-VH orientation;
(9) a) the VH contains Cys in H3;
b) said VL contains Cys at L39;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VL-L-VH orientation;
(10) a) the VH contains Cys in H43;
b) said VL contains Cys in L100,
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(11) a) the VH contains Cys in H43;
b) said VL contains Cys at L102;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(12) a) the VH contains Cys in H43;
b) said VL comprises Cys in L5,
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(13) a) the VH contains Cys in H43;
b) said VL contains Cys in L3,
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(14) a) the VH contains Cys in H40,
b) said VL contains Cys in L100,
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(15) a) the VH contains Cys in H40,
b) said VL contains Cys at L102;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(16) a) the VH contains Cys in H40,
b) said VL comprises Cys in L5,
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(17) a) the VH contains Cys in H40,
b) said VL contains Cys in L3,
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(18) a) the VH contains Cys in H46;
b) said VL contains Cys in L100,
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(19) a) the VH contains Cys in H46;
b) said VL contains Cys at L102;
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation;
(20) a) the VH contains Cys in H46;
b) said VL comprises Cys in L5,
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation, or
(21) a) the VH contains Cys in H46;
b) said VL contains Cys in L3,
c) said L comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6 or 7;
d) said scFv is in the VH-L-VL orientation,
scFv.
前記Lが、配列番号6のアミノ酸配列を含むか、又は
前記Lが、配列番号7のアミノ酸配列を含む、
請求項14に記載のscFv。 said L comprises the amino acid sequence of SEQ ID NO: 3 ;
said L comprises the amino acid sequence of SEQ ID NO: 6, or
wherein said L comprises the amino acid sequence of SEQ ID NO:7;
The scFv of claim 14 .
前記第2の分子が、細胞傷害性薬剤又は検出可能な標識であるか、
前記第2の分子が、抗体又はその断片であるか、又は
前記第2の分子が、キメラ抗原受容体(CAR)である、
請求項16に記載のscFv。 said second molecule is a half-life extending moiety ;
whether said second molecule is a cytotoxic agent or a detectable label;
said second molecule is an antibody or fragment thereof, or
wherein said second molecule is a chimeric antigen receptor (CAR);
The scFv of claim 16 .
前記scFv及び前記抗体又は前記その断片が、異なる抗原に結合する、
請求項17に記載のscFv。 said half-life extending moiety is an immunoglobulin (Ig), a fragment of said Ig, an Ig constant region, a fragment of said Ig constant region, an Fc region, transferrin, albumin, an albumin binding domain or polyethylene glycol , or
said scFv and said antibody or said fragment thereof bind to different antigens;
The scFv of claim 17 .
前記宿主細胞が、真核細胞である、
請求項23に記載の方法。 said host cell is a prokaryotic cell , or
said host cell is a eukaryotic cell;
24. The method of claim 23 .
前記多重特異性タンパク質が、Ig定常領域又は前記Ig定常領域の断片を含む、
請求項27に記載の多重特異性分子。 said multispecific molecule comprises an antibody or antibody fragment , or
said multispecific protein comprises an Ig constant region or a fragment of said Ig constant region;
28. The multispecific molecule of claim 27 .
前記Ig定常領域の前記断片が、CH2ドメインを含むか、
前記Ig定常領域の前記断片が、CH3ドメインを含むか、
前記Ig定常領域の前記断片が、前記CH2ドメインと、前記CH3ドメインと、を含むか、
前記Ig定常領域の前記断片が、ヒンジの少なくとも一部分、前記CH2ドメイン及び前記CH3ドメインを含むか、又は
前記Ig定常領域の前記断片が、前記ヒンジと、前記CH2ドメインと、前記CH3ドメインと、を含む、
請求項28に記載の多重特異性タンパク質。 said fragment of said Ig constant region comprises an Fc region ;
said fragment of said Ig constant region comprises a CH2 domain;
said fragment of said Ig constant region comprises a CH3 domain;
said fragment of said Ig constant region comprises said CH2 domain and said CH3 domain;
said fragment of said Ig constant region comprises at least a portion of the hinge, said CH2 domain and said CH3 domain, or
said fragment of said Ig constant region comprises said hinge, said CH2 domain and said CH3 domain;
29. The multispecific protein of claim 28 .
前記scFvが、前記Ig定常領域のC末端又は前記Ig定常領域の前記断片のN末端に共役される、
請求項28又は29に記載の多重特異性分子。 said scFv is conjugated to the N-terminus of said Ig constant region or to the N-terminus of said fragment of said Ig constant region , or
said scFv is conjugated to the C-terminus of said Ig constant region or the N-terminus of said fragment of said Ig constant region;
30. A multispecific molecule according to claim 28 or 29 .
前記Ig定常領域又は前記Ig定常領域の前記断片が、前記多重特異性分子のFcγRへの結合を低減する少なくとも1つの変異を含む、
請求項28~30のいずれか一項に記載の多重特異性分子。 said Ig constant region or said fragment of said Ig constant region is of IgG1, IgG2, and IgG3 or IgG4 isotypes, and/or
said Ig constant region or said fragment of said Ig constant region comprises at least one mutation that reduces binding of said multispecific molecule to an FcγR;
Multispecific molecule according to any one of claims 28-30 .
前記多重特異性分子が、三重特異性であるか、又は
前記多重特異性分子が、四重特異性である、
請求項27~39のいずれか一項に記載の多重特異性分子。 said multispecific molecule is bispecific ;
said multispecific molecule is trispecific, or
said multispecific molecule is tetraspecific;
Multispecific molecule according to any one of claims 27-39 .
前記第2のタンパク質が、代替スカフォールドであるか、又は
前記第2のタンパク質が、キメラ抗原受容体(CAR)又はその断片である、
請求項43に記載の異種分子。 the second protein is an antibody or fragment thereof ;
said second protein is an alternative scaffold, or
wherein said second protein is a chimeric antigen receptor (CAR) or a fragment thereof;
44. The heterologous molecule of claim 43 .
前記異種分子が、多重特異性である、
請求項42~44のいずれか一項に記載の異種分子。 said heterologous molecule is monospecific , or
said heterologous molecule is multispecific;
A heterologous molecule according to any one of claims 42-44 .
前記異種分子が、三重特異性であるか、又は
前記異種分子が、四重特異性である、
請求項45に記載の異種分子。 said heterologous molecule is bispecific;
said heterologous molecule is trispecific, or
said heterologous molecule is tetraspecific;
46. The heterologous molecule of claim 45 .
抗原結合ドメインを形成する重鎖可変領域(VH)及び軽鎖可変領域(VL)を提供することと、
第1のL Cysを含むか、又はそれを含むように操作されたリンカー(L)を提供することと、
構造的に保存された表面露出VHフレームワーク残基位置でVH Cysを含むように前記VHを操作することと、
前記VH Cysと前記第1のL Cysとの間にジスルフィド結合を形成して、前記安定化scFvを調製することと、を含む、プロセス。 A process for preparing a stabilized scFv comprising:
providing a heavy chain variable region (VH) and a light chain variable region (VL) that form an antigen binding domain;
providing a linker (L) comprising or engineered to comprise the first L Cys;
engineering said VH to include VH Cys at structurally conserved, surface-exposed VH framework residue positions;
forming a disulfide bond between said VH Cys and said first L Cys to prepare said stabilized scFv.
抗原結合ドメインを形成するVH及びVLを提供することと、
第2のL Cysを含むか、又はそれを含むように操作されたLを提供することと、
構造的に保存された表面露出VLフレームワーク残基位置にVL Cysを含むように前記VLを操作することと、
前記VL Cysと前記第2のL Cysとの間にジスルフィド結合を形成して、前記安定化scFvを調製することと、を含む、プロセス。 A process for preparing a stabilized scFv comprising:
providing VH and VL that form an antigen binding domain;
providing L containing or engineered to contain a second L Cys;
engineering said VL to include VL Cys at structurally conserved, surface-exposed VL framework residue positions;
forming a disulfide bond between said VL Cys and said second L Cys to prepare said stabilized scFv.
抗原結合ドメインを形成するVH及びVLを提供することと、
第1のL Cys及び第2のL Cysを含むか、又はそれらを含むように操作されたLを提供することと、
構造的に保存された表面露出VHフレームワーク残基位置にVH Cysを含むように前記VHを操作することと、
構造的に保存された表面露出VLフレームワーク残基位置にVL Cysを含むように前記VLを操作することと、
前記VH Cysと前記第1のL Cysとの間にジスルフィド結合を形成し、前記VL Cysと前記第2のL Cysとの間にジスルフィド結合を形成して、前記安定化scFvを調製することと、を含む、プロセス。 A process for preparing a stabilized scFv comprising:
providing VH and VL that form an antigen binding domain;
providing L comprising or engineered to comprise a first L Cys and a second L Cys;
engineering said VH to include VH Cys at structurally conserved, surface-exposed VH framework residue positions;
engineering said VL to include VL Cys at structurally conserved surface-exposed VL framework residue positions;
forming a disulfide bond between the VH Cys and the first L Cys and a disulfide bond between the VL Cys and the second L Cys to prepare the stabilized scFv; , including, the process.
a)VH、L及びVLをコードするポリヌクレオチドを提供することであって、
i.前記VHが、H105にCysを含み、前記VLが、L42にCysを含むか、
ii.前記VHが、H43にCysを含み、前記VLが、L100にCysを含むか、
iii.前記VHが、H3にCysを含み、前記VLが、L3にCysを含むか、
iv.前記VHが、H3にCysを含み、前記VLが、L5にCysを含むか、
v.前記VHが、H3にCysを含み、前記VLが、L39にCysを含むか、
vi.前記VHが、H3にCysを含み、前記VLが、L42にCysを含むか、
vii.前記VHが、H3にCysを含み、前記VLが、L45にCysを含むか、
viii.前記VHが、H3にCysを含み、前記VLが、L100にCysを含むか、
ix.前記VHが、H3にCysを含み、前記VLが、L102にCysを含むか、
x.前記VHが、H5にCysを含み、前記VLが、L3にCysを含むか、
xi.前記VHが、H5にCysを含み、前記VLが、L5にCysを含むか、
xii.前記VHが、H5にCysを含み、前記VLが、L39にCysを含むか、
xiii.前記VHが、H5にCysを含み、前記VLが、L42にCysを含むか、
xiv.前記VHが、H5にCysを含み、前記VLが、L45にCysを含むか、
xv.前記VHが、H5にCysを含み、前記VLが、L100にCysを含むか、
xvi.前記VHが、H5にCysを含み、前記VLが、L102にCysを含むか、
xvii.前記VHが、H40にCysを含み、前記VLが、L3にCysを含むか、
xviii.前記VHが、H40にCysを含み、前記VLが、L5にCysを含むか、
xix.前記VHが、H40にCysを含み、前記VLが、L39にCysを含むか、
xx.前記VHが、H40にCysを含み、前記VLが、L42にCysを含むか、
xxi.前記VHが、H40にCysを含み、前記VLが、L45にCysを含むか、
xxii.前記VHが、H40にCysを含み、前記VLが、L100にCysを含むか、
xxiii.前記VHが、H40にCysを含み、前記VLが、L102にCysを含むか、
xxiv.前記VHが、H43にCysを含み、前記VLが、L3にCysを含むか、
xxv.前記VHが、H43にCysを含み、前記VLが、L5にCysを含むか、
xxvi.前記VHが、H43にCysを含み、前記VLが、L39にCysを含むか、
xxvii.前記VHが、H43にCysを含み、前記VLが、L42にCysを含むか、
xxviii.前記VHが、H43にCysを含み、前記VLが、L45にCysを含むか、
xxix.前記VHが、H43にCysを含み、前記VLが、L102にCysを含むか、
xxx.前記VHが、H46にCysを含み、前記VLが、L3にCysを含むか、
xxxi.前記VHがH46にCysを含み、前記VLが、L5にCysを含むか、
xxxii.前記VHが、H46にCysを含み、前記VLが、L39にCysを含むか、
xxxiii.前記VHが、H46にCysを含み、前記VLが、L42にCysを含むか、
xxxiv.前記VHが、H46にCysを含み、前記VLが、L45にCysを含むか、
xxxv.前記VHが、H46にCysを含み、前記VLが、L100にCysを含むか、
xxxvi.前記VHが、H46にCysを含み、前記VLが、L102にCysを含むか、
xxxvii.前記VHが、H105にCysを含み、前記VLが、L3にCysを含むか、
xxxviii.前記VHが、H105にCysを含み、前記VLが、L5にCysを含むか、
xxxix.前記VHが、H105にCysを含み、前記VLが、L39にCysを含むか、
xl.前記VHが、H105にCysを含み、前記VLが、L45にCysを含むか、
xli.前記VHが、H105にCysを含み、前記VLが、L100にCysを含むか、又は
xlii.前記VHが、H105にCysを含み、前記VLが、L102にCysを含み、
残基番号付けが、Chothiaに従う、提供することと、
b)前記Lが、配列番号3、4、5、6、又は7のアミノ酸配列を含むことと、
c)宿主細胞内で前記ポリヌクレオチドを発現させて、前記安定化scFvを産生することと、を含む、プロセス。 A process for preparing a stabilized scFv comprising:
a) providing polynucleotides encoding VH, L and VL,
i. said VH comprises Cys at H105 and said VL comprises Cys at L42;
ii. said VH comprises Cys at H43 and said VL comprises Cys at L100;
iii. said VH comprises Cys in H3 and said VL comprises Cys in L3;
iv. said VH comprises Cys at H3 and said VL comprises Cys at L5;
v. said VH comprises Cys at H3 and said VL comprises Cys at L39;
vi. said VH comprises Cys at H3 and said VL comprises Cys at L42;
vii. said VH comprises Cys at H3 and said VL comprises Cys at L45;
viii. said VH comprises Cys in H3 and said VL comprises Cys in L100;
ix. said VH comprises Cys at H3 and said VL comprises Cys at L102;
x. said VH comprises Cys at H5 and said VL comprises Cys at L3;
xi. said VH comprises Cys at H5 and said VL comprises Cys at L5;
xii. said VH comprises Cys at H5 and said VL comprises Cys at L39;
xiii. said VH comprises Cys at H5 and said VL comprises Cys at L42;
xiv. said VH comprises Cys at H5 and said VL comprises Cys at L45;
xv. said VH comprises Cys at H5 and said VL comprises Cys at L100;
xvi. said VH comprises Cys at H5 and said VL comprises Cys at L102;
xvii. said VH comprises Cys at H40 and said VL comprises Cys at L3;
xviii. said VH comprises Cys at H40 and said VL comprises Cys at L5;
xix. said VH comprises Cys at H40 and said VL comprises Cys at L39;
xx. said VH comprises Cys at H40 and said VL comprises Cys at L42;
xxi. said VH comprises Cys at H40 and said VL comprises Cys at L45;
xxii. said VH comprises Cys in H40 and said VL comprises Cys in L100;
xxiii. said VH comprises Cys at H40 and said VL comprises Cys at L102;
xxiv. said VH comprises Cys at H43 and said VL comprises Cys at L3;
xxv. said VH comprises Cys at H43 and said VL comprises Cys at L5;
xxvi. said VH comprises Cys at H43 and said VL comprises Cys at L39;
xxvii. said VH comprises Cys at H43 and said VL comprises Cys at L42;
xxviii. said VH comprises Cys at H43 and said VL comprises Cys at L45;
xxix. said VH comprises Cys at H43 and said VL comprises Cys at L102;
xxx. said VH comprises Cys at H46 and said VL comprises Cys at L3;
xxxi. said VH comprises Cys at H46 and said VL comprises Cys at L5;
xxxii. said VH comprises Cys at H46 and said VL comprises Cys at L39;
xxxiii. said VH comprises Cys at H46 and said VL comprises Cys at L42;
xxxiv. said VH comprises Cys at H46 and said VL comprises Cys at L45;
xxxv. said VH comprises Cys at H46 and said VL comprises Cys at L100;
xxxvi. said VH comprises Cys at H46 and said VL comprises Cys at L102;
xxxvii. said VH comprises Cys at H105 and said VL comprises Cys at L3;
xxxviii. said VH comprises Cys at H105 and said VL comprises Cys at L5;
xxxix. said VH comprises Cys at H105 and said VL comprises Cys at L39;
xl. said VH comprises Cys at H105 and said VL comprises Cys at L45;
xli. said VH comprises Cys at H105 and said VL comprises Cys at L100, or xlii. the VH contains Cys at H105, the VL contains Cys at L102,
providing residue numbering according to Chothia;
b) said L comprises the amino acid sequence of SEQ ID NO: 3 , 4, 5, 6, or 7;
c) expressing said polynucleotide in a host cell to produce said stabilized scFv.
前記宿主細胞が、真核細胞である、
請求項53に記載の方法。 said host cell is a prokaryotic cell , or
said host cell is a eukaryotic cell;
54. The method of claim 53 .
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、scFv。 An isolated single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a means for joining (L), and a light chain variable region (VL), wherein said scFv comprises
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between the structurally conserved surface-exposed VL Cys and the second L Cys, or c) said structurally conserved surface-exposed VH Cys and said first L Cys. and said second disulfide bond between said structurally conserved surface-exposed VL Cys and said second L Cys.
a)構造的に保存された表面露出抗原結合手段システイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出抗原結合手段Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、scFv。 An isolated single chain variable fragment (scFv) comprising a means for antigen binding, a linker (L) and a light chain variable region (VL), said scFv comprising:
a) the first disulfide bond between the structurally conserved surface-exposed antigen binding means cysteine (Cys) and the first L Cys;
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or c) said structurally conserved surface-exposed antigen binding means Cys and said first L a scFv comprising said first disulfide bond between Cys and said second disulfide bond between said structurally conserved surface-exposed VL Cys and said second L Cys.
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出抗原結合手段Cysと、第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出抗原結合手段Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、scFv。 An isolated single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a linker (L) and means for antigen binding, said scFv comprising:
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between a structurally conserved surface-exposed antigen binding means Cys and a second L Cys, or c) a second disulfide bond between said structurally conserved surface-exposed VH Cys and said first scFv comprising said first disulfide bond between L Cys and said second disulfide bond between said structurally conserved surface-exposed antigen binding means Cys and said second L Cys.
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、多重特異性分子。 A multispecific molecule comprising a single chain variable fragment (scFv) comprising a heavy chain variable region (VH), means for linking (L) and a light chain variable region (VL), wherein said scFv is ,
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between the structurally conserved surface-exposed VL Cys and the second L Cys, or c) said structurally conserved surface-exposed VH Cys and said first L Cys. and said second disulfide bond between said structurally conserved surface-exposed VL Cys and said second L Cys.
a)構造的に保存された表面露出抗原結合手段システイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出抗原結合手段Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、多重特異性分子。 A multispecific molecule comprising a single chain variable fragment (scFv) comprising a means for antigen binding, a linker (L) and a light chain variable region (VL), said scFv comprising:
a) the first disulfide bond between the structurally conserved surface-exposed antigen binding means cysteine (Cys) and the first L Cys;
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or c) a second disulfide bond between said structurally conserved surface-exposed antigen binding means Cys and said first A multispecific molecule comprising said first disulfide bond between L Cys and said second disulfide bond between said structurally conserved surface-exposed VL Cys and said second L Cys.
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出抗原結合手段Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出抗原結合手段Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合と、を含む、多重特異性分子。 A multispecific molecule comprising a single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a linker (L) and means for antigen binding (VL), said scFv comprising:
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between the structurally conserved surface-exposed antigen binding means Cys and the second L Cys, or c) said structurally conserved surface-exposed VH Cys and said first L Cys. said first disulfide bond between Cys and said second disulfide bond between said structurally conserved surface-exposed antigen binding means Cys and said second L Cys. molecule.
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、異種分子。 A heterologous molecule comprising a single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a means for linking (L) and a light chain variable region (VL), said scFv comprising:
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between the structurally conserved surface-exposed VL Cys and the second L Cys, or c) said structurally conserved surface-exposed VH Cys and said first L Cys. and said second disulfide bond between said structurally conserved surface-exposed VL Cys and said second L Cys.
a)構造的に保存された表面露出抗原結合手段システイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出VL Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出抗原結合手段Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出VL Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、異種分子。 A heterologous molecule comprising a single chain variable fragment (scFv) comprising a means for antigen binding, a linker (L) and a light chain variable region (VL), said scFv comprising:
a) the first disulfide bond between the structurally conserved surface-exposed antigen binding means cysteine (Cys) and the first L Cys;
b) a second disulfide bond between a structurally conserved surface-exposed VL Cys and a second L Cys, or c) said structurally conserved surface-exposed antigen binding means Cys and said first L a heterologous molecule comprising said first disulfide bond between Cys and said second disulfide bond between said structurally conserved surface-exposed VL Cys and said second L Cys.
a)構造的に保存された表面露出VHシステイン(Cys)と第1のL Cysとの間の第1のジスルフィド結合、
b)構造的に保存された表面露出抗原結合手段Cysと第2のL Cysとの間の第2のジスルフィド結合、又は
c)前記構造的に保存された表面露出VH Cysと前記第1のL Cysとの間の前記第1のジスルフィド結合及び前記構造的に保存された表面露出抗原結合手段Cysと前記第2のL Cysとの間の前記第2のジスルフィド結合、を含む、異種分子。 A heterologous molecule comprising a single chain variable fragment (scFv) comprising a heavy chain variable region (VH), a linker (L) and means for antigen binding, said scFv comprising:
a) the first disulfide bond between the structurally conserved surface-exposed VH cysteine (Cys) and the first L Cys,
b) a second disulfide bond between the structurally conserved surface-exposed antigen binding means Cys and the second L Cys, or c) said structurally conserved surface-exposed VH Cys and said first L Cys. A heterologous molecule comprising said first disulfide bond between Cys and said second disulfide bond between said structurally conserved surface-exposed antigen binding means Cys and said second L Cys.
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962887524P | 2019-08-15 | 2019-08-15 | |
US201962887514P | 2019-08-15 | 2019-08-15 | |
US201962887529P | 2019-08-15 | 2019-08-15 | |
US201962887519P | 2019-08-15 | 2019-08-15 | |
US201962887527P | 2019-08-15 | 2019-08-15 | |
US62/887,519 | 2019-08-15 | ||
US62/887,514 | 2019-08-15 | ||
US62/887,529 | 2019-08-15 | ||
US62/887,527 | 2019-08-15 | ||
US62/887,524 | 2019-08-15 | ||
US201962946877P | 2019-12-11 | 2019-12-11 | |
US201962946882P | 2019-12-11 | 2019-12-11 | |
US201962946897P | 2019-12-11 | 2019-12-11 | |
US201962946886P | 2019-12-11 | 2019-12-11 | |
US201962946865P | 2019-12-11 | 2019-12-11 | |
US62/946,877 | 2019-12-11 | ||
US62/946,865 | 2019-12-11 | ||
US62/946,897 | 2019-12-11 | ||
US62/946,886 | 2019-12-11 | ||
US62/946,882 | 2019-12-11 | ||
PCT/US2020/046303 WO2021030657A1 (en) | 2019-08-15 | 2020-08-14 | Materials and methods for improved single chain variable fragments |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022544760A JP2022544760A (en) | 2022-10-21 |
JPWO2021030657A5 true JPWO2021030657A5 (en) | 2023-08-15 |
Family
ID=72243247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022507875A Pending JP2022544760A (en) | 2019-08-15 | 2020-08-14 | Materials and methods for improved single-chain variable fragments |
Country Status (18)
Country | Link |
---|---|
US (2) | US11787875B2 (en) |
EP (1) | EP4013783A1 (en) |
JP (1) | JP2022544760A (en) |
KR (1) | KR20220062494A (en) |
CN (1) | CN114258400A (en) |
AU (1) | AU2020328049A1 (en) |
BR (1) | BR112022002540A2 (en) |
CA (1) | CA3148121A1 (en) |
CO (1) | CO2022001222A2 (en) |
CR (1) | CR20220054A (en) |
DO (1) | DOP2022000032A (en) |
EC (1) | ECSP22011199A (en) |
IL (1) | IL290436A (en) |
JO (1) | JOP20220035A1 (en) |
MX (1) | MX2022001799A (en) |
PE (1) | PE20220299A1 (en) |
TW (1) | TW202120537A (en) |
WO (1) | WO2021030657A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023506750A (en) * | 2019-12-11 | 2023-02-20 | シラグ・ゲーエムベーハー・インターナショナル | Multispecific binding molecules comprising LTBR and EDB binding domains and uses thereof |
WO2023089587A1 (en) * | 2021-11-22 | 2023-05-25 | Janssen Biotech, Inc. | Compositions comprising enhanced multispecific binding agents for an immune response |
WO2023152581A1 (en) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Method of treating cancer with psmaxcd3 antibody |
WO2023164510A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
WO2024028731A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
DE102005028778A1 (en) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food |
PT1999154E (en) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
MX2009010639A (en) | 2007-04-02 | 2009-10-23 | Philogen Spa | The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases. |
JP2011507519A (en) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN102089431A (en) * | 2008-06-30 | 2011-06-08 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | Functionalized polypeptides |
CN102459346B (en) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | The method manufacturing heteromultimers molecule |
EP2445936A1 (en) | 2009-06-26 | 2012-05-02 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
CA2769619C (en) | 2009-08-17 | 2019-04-30 | Roche Glycart Ag | Targeted immunoconjugates |
ES2667258T3 (en) * | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Multivalent antibodies |
AU2010336029B2 (en) * | 2009-12-23 | 2011-10-13 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
CN103068846B9 (en) * | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | Bispecific antibodies comprising disulfide-stabilized Fv fragments |
RS59589B1 (en) | 2010-11-05 | 2019-12-31 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the fc domain |
TWI588156B (en) * | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
EP2771364B1 (en) | 2011-10-27 | 2019-05-22 | Genmab A/S | Production of heterodimeric proteins |
CN104080811B (en) | 2011-11-04 | 2019-09-27 | 酵活有限公司 | There is the antibody design of the stabilization heterodimeric of mutation in Fc structural domain |
DK2794905T3 (en) | 2011-12-20 | 2020-07-06 | Medimmune Llc | MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY BASIC STRUCTURES |
NZ772318A (en) | 2012-04-20 | 2023-06-30 | Merus Nv | Methods and means for the production of ig-like molecules |
WO2013175678A1 (en) * | 2012-05-24 | 2013-11-28 | パナソニック株式会社 | Variant protein capable of binding specifically and rapidly to human cardiac troponin i |
SG11201507577RA (en) | 2013-03-15 | 2015-10-29 | Janssen Biotech Inc | Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins |
JP7022123B2 (en) | 2016-09-30 | 2022-02-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antibody against CD3 |
EP3684816B1 (en) | 2017-09-22 | 2024-05-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
-
2020
- 2020-08-14 WO PCT/US2020/046303 patent/WO2021030657A1/en active Application Filing
- 2020-08-14 TW TW109127754A patent/TW202120537A/en unknown
- 2020-08-14 CA CA3148121A patent/CA3148121A1/en active Pending
- 2020-08-14 US US16/994,065 patent/US11787875B2/en active Active
- 2020-08-14 JP JP2022507875A patent/JP2022544760A/en active Pending
- 2020-08-14 CN CN202080057404.8A patent/CN114258400A/en active Pending
- 2020-08-14 PE PE2022000220A patent/PE20220299A1/en unknown
- 2020-08-14 JO JOP/2022/0035A patent/JOP20220035A1/en unknown
- 2020-08-14 MX MX2022001799A patent/MX2022001799A/en unknown
- 2020-08-14 BR BR112022002540A patent/BR112022002540A2/en unknown
- 2020-08-14 AU AU2020328049A patent/AU2020328049A1/en active Pending
- 2020-08-14 KR KR1020227004708A patent/KR20220062494A/en unknown
- 2020-08-14 CR CR20220054A patent/CR20220054A/en unknown
- 2020-08-14 EP EP20761987.5A patent/EP4013783A1/en active Pending
-
2022
- 2022-02-07 CO CONC2022/0001222A patent/CO2022001222A2/en unknown
- 2022-02-08 DO DO2022000032A patent/DOP2022000032A/en unknown
- 2022-02-08 IL IL290436A patent/IL290436A/en unknown
- 2022-02-11 EC ECSENADI202211199A patent/ECSP22011199A/en unknown
-
2023
- 2023-09-05 US US18/461,191 patent/US20240067754A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111246885B (en) | Method for generating multispecific antibodies from monospecific antibodies | |
US20190263909A1 (en) | Bispecific and monospecific antibodies using novel anti-pd-1 sequences | |
JP2020522266A5 (en) | ||
JP6742245B2 (en) | Multispecific antibody | |
EP2435473B1 (en) | Tri- or tetraspecific antibodies | |
RU2018108103A (en) | STRUCTURES HAVING A SIRP-α DOMAIN OR ITS OPTION | |
RU2019108429A (en) | MODIFIED ASYMMETRIC ANTIBODIES CONNECTING FC-RECEPTOR AND METHODS OF THEIR APPLICATION | |
CA2917886A1 (en) | Bispecific cd3 and cd19 antigen binding constructs | |
RU2015101699A (en) | Fused polypeptides and conjugates of the ligand receptor ligand of the receptor of incretin and the FC region with an altered FC effect function | |
US20200140568A1 (en) | Biparatopic and multiparatopic antibodies with common light chain and method of use | |
CA2876099A1 (en) | Method for producing monomeric and multimeric molecules and uses thereof | |
US20220119549A1 (en) | Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof | |
CA3078676A1 (en) | Method for in vivo generation of multispecific antibodies from monospecific antibodies | |
JPWO2021030657A5 (en) | ||
Mimoto et al. | Fc engineering to improve the function of therapeutic antibodies | |
CA3133898A1 (en) | Activatable therapeutic multispecific polypeptides with extended half-life | |
JPWO2021019389A5 (en) | ||
CA3203831A1 (en) | Bi- or multi-specific antibody | |
JPWO2019140273A5 (en) | ||
RU2021121021A (en) | METHODS FOR PRODUCING HETERODIMERIC ANTIBODIES | |
JPWO2020128870A5 (en) | ||
JPWO2021240388A5 (en) | ||
TW202233663A (en) | Novel linkers of multispecific antigen binding domains | |
JPWO2021030488A5 (en) |